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Breast Cancer Risk: Environmental 
and Genetic effects in Cancer 
Development, Progression and 
Survival 
Abstract 
Breast cancer is a common, complex multifactorial disease which has an estimated risk in 
the UK of 1 in 9 women.  Due to its prevalence there has been a great deal of research 
carried out to identify risk and prognostic factors which are involved in its pathogenesis.  By 
reviewing this vast array of literature conclusions have been drawn as to which factors are 
consistently associated with risk and prognosis.  These include high penetrance genetic 
factors such as BRCA1, BRCA1, PTEN; and low penetrance mutations including FGFR2, 
CASP8 and ESR1.  Additionally environmental factors influence risk, including reproductive 
factors, alcohol consumption, smoking and social deprivation.  Of the factors identified in 
this literature review there was evidence that there may be common biological 
mechanisms underlying their role in breast cancer risk.  For example, oestrogen signalling 
pathways and DNA repair pathways were commonly proposed as the mechanism 
underlying both genetic and environmental risk.   
To demonstrate the impact of environmental risk factors on breast cancer outcome a 
survival analysis was carried out on 1851 women diagnosed with primary breast cancer 
between 2000 and 2004.  Using SPSS to analyse the data it was found that women from the 
most deprived areas in Tayside had the poorest breast cancer outcome – these outcomes 
included all-cause mortality, breast cancer specific death and breast cancer recurrence.  
When the analysis was adjusted for staging information the significant difference in breast 
cancer specific 5 year survival was lost.  Therefore this suggests that deprived women 
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present with higher stage tumours, which is one of the reasons underlying their poorer 
outcome.   
This thesis clarifies the risk and prognostic factors associated with breast cancer, and 
demonstrated that in a Tayside cohort deprivation is associated with poor outcome.  In 
addition common biological mechanisms have been identified as associated with these risk 
factors.  It is only through thinking of breast cancer in a holistic manner and incorporating 
different aspects of breast cancer pathogenesis a better understanding of the disease can 
be gained, and new risk factors identified.  By understanding this better it is hoped that this 
will lead to improved preventative measures and the development of more targeted 
treatment options.  
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Breast Cancer Risk – Environmental 
and Genetic Effects on Cancer 
Development, Progression and 
Survival 
Introduction 
Breast cancer is the most common cancer affecting women; in 2008 there were an 
estimated 1.38 million cases diagnosed worldwide, with the highest incidence in Western 
Europe(1).  It is also the most common female cancer in the UK, with a population risk of 
approximately 1 in 8 women(1).  Due to its high prevalence there has been a great deal of 
research to elucidate the aetiology and optimise the management of the disease.  However 
this has been a difficult area of research as breast cancer is a heterogeneous multifactorial 
disease, which involves a complex interplay between environmental and genetic factors(2).   
The incidence of breast cancer has been steadily rising worldwide since the beginning of 
the 20th century.  This increase may be due to a multitude of factors including the 
introduction of screening programs, environmental and societal changes.  However, this 
has been matched by a trend towards increased expected survival over recent years which 
continues to increase(3).  This increase in survival may be attributable to various factors 
including improved awareness, early detection and better clinical management. 
It is also important to note that there are many forms of breast cancer, as it is 
heterogeneous disease which has many different pathological appearances and therefore 
clinical courses.  These can initially be broken down into invasive or in situ carcinoma, these 
in situ lesions are not breast cancer they are a form of breast disease(4).  There are two in 
situ lesions – ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS).  DCIS is 
relatively common breast disease and accounts for 20-30% of the lesions picked up by the 
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screening program.  However approximately 35% of these DCIS cases will then go on to 
become an invasive carcinoma, which is why DCIS is treated in an aggressive manner 
despite not being a cancer.  There are also various types of invasive lesions, the most 
common of which is ductal carcinoma, otherwise known as no specific type (NST), which 
accounts for about 50% of all breast cancers(5).  Other varieties of breast carcinoma 
include lobular, tubular, medullary and mucinous carcinomas; all of which have a distinct 
pathological appearance.  
In addition to the distinct pathological forms of the disease there are also a number of 
predictive factors, which include oestrogen receptor (ER), progesterone receptor (PR) 
and/or human epidermal factor receptor 2 (HER2) expression(6).  A positive receptor status 
indicates that these tumours may be responsive to that particular hormone and this helps 
to predict patient prognosis, and informs the potential management options.  These 
management options refer specifically to adjuvant therapies, such as tamoxifen used in ER 
positive tumours which targets the oestrogen signalling pathway.  However it is also 
important to note that a positive receptor status does not mean that these tumours will 
definitely be responsive to these adjuvant therapies.  Other management options include 
radiotherapy, chemotherapy and surgical management – the management plan chosen is 
dependent on the type, pathological characteristics and stage of tumour at diagnosis(4).  
However, regardless of the subtype of breast cancer there appear to be common risk 
factors and prognostic factors which contribute to the pathogenesis and outcome of the 
disease.   
This thesis aims to assess the evidence for factors which contribute to breast cancer risk 
and prognosis.  As stated above breast cancer is a complex multifactorial disease which has 
a variety of environmental, reproductive and genetic risk factors at play.  A number of the 
reproductive and environmental risk factors shall be reviewed in a journalistic literature 
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review to assess their contribution to risk and the mechanism by which they influence risk.  
This shall be followed with a similar review of the genetic factors which contribute to risk, 
including the contribution of both high risk genetic changes and low penetrance single 
nucleotide polymorphisms (SNP).  The environmental factors which contribute to 
prognosis, many of which will have been reviewed with regards to risk, shall also be 
investigated in the same way.  This large literature review will be followed by a survival 
analysis of a Tayside cohort, which incorporates some of the prognostic factors previously 
discussed.   
Due to the vast amount of literature on this subject it is not always clear what 
epidemiological and genetic factors contribute breast cancer development.  However, the 
above proposed structure shall allow this thesis to review this evidence and arrive at 
several conclusions.  This will allow for some key research questions to be answered, which 
will hopefully add to the current understanding of breast cancer as a multifactorial 
heterogeneous disease.  These include:  
 What environmental and genetic factors contribute to breast cancer risk and by what 
mechanisms?   
 Do similar factors contribute to breast cancer outcome?   
 Do these genetic and environmental factors interact with each other to change this 
contribution to risk?  
 Are there common pathways which link these genetic and environmental factors?   
 Finally, what is the current breast cancer survival in a small cohort?  Does deprivation, 
one of the studied prognostic and risk factors, have any effect on breast cancer 
survival?   
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This multifactorial approach to breast cancer aims to provide a well-rounded holistic view 
of the numerous factors which contribute to the development, progression and outcome of 
breast cancer.  An original survival analysis shall be utilised to gain further understanding of 
how these factors contribute to outcome.  Due to the complex heterogeneity of breast 
cancer and the many elements which contribute to the disease, an understanding of the 
processes involved in the disease itself requires looking at these elements together and 
how they may interact.  In the process of achieving these goals this thesis hopes to provide 
a comprehensive overview of breast cancer risk and prognostic factors that are commonly 
accepted as contributing to the disease process.  
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Genetic Factors Contributing to 
Breast Cancer Risk  
1. Introduction 
There are two major types of genetic factors which are known to be involved in the 
pathogenesis of breast cancer.  The first of which are highly penetrant mutations inherited 
in an autosomal dominant manner; these include breast cancer 1 early onset (BRCA1) and 
breast cancer 2 early onset (BRCA2).  The second form of inherited breast cancer risk, are 
low penetrance polymorphisms which confer an increased risk but are not causative of the 
disease.  There have been 18 of these low penetrance polymorphisms identified and 
generally accepted as having an impact on breast cancer risk(7,8). 
This literature review was conducted in a journalistic style based in part on a predefined list 
of breast cancer susceptibility genes, which were the first 18 SNPs and higher penetrance 
genes to be consistently linked with breast cancer risk.  For each gene a Medline search 
was conducted using Breast Neoplasm and an appropriate term for the gene summarised 
in Appendix 1. During this review of the literature other genetic risk factors out with this 
pre-defined list were also identified, and therefore included in this review.    
Throughout the course of this chapter the contributions of the different genetic factors to 
breast cancer risk and pathogenesis shall be discussed.  This will also include a brief look at 
the risk conferred by a family history of breast cancer, followed by a discussion of the 
known genetic factors which contribute to breast cancer risk. 
2. Family History 
Family history was first noted as contributing to breast cancer risk by the French physician 
Paul Broca in 1866, who identified there were families with multiple cases of the 
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disease(9).  There has been a huge amount of research in this field with the vast majority of 
the epidemiological work showing a positive association between family history and breast 
cancer risk.  However relative risks have been shown to vary due to a number of factors; 
including the age of the individual, the nature and extent of the family history(9).  The 
increased risk associated with family history will be due to genetics, and also in part to 
shared environments and social factors. 
A large meta-analysis was carried out in 1997 by Pharoah et al(9), which assessed 74 
studies to identify the relationship between family history and risk in a large population.  
They found that the results tended to remain similar regardless of study design (e.g. 
prospective, retrospective cohorts, case-control and hospital case-control), with RR 
(relative risk) ranging from 1.6 to 2.5 for those with affected first degree relatives.  These 
results can be considered to represent the true relationship between family history and 
breast cancer risk, due to their homogeneity despite differing methodologies.  When 
assessing the risk associated with different family members they found the results 
summarised in Table 1.1.  The results of this study highlights that relative risk increases 
with increasing number of first degree relatives affected by the disease and younger age at 
diagnosis.  
These results were replicated by a second re-analysis by the Collaborative Group on 
Hormonal Factors (2001), who looked at 54 studies in total(10).  Initial analysis of the 
population across the studies highlighted that 12.9% of cases and 7.3% of controls had one 
or more affected first degree relative.  This therefore demonstrates that a greater number 
of women with breast cancer also had an affected relative. The risk increased significantly 
with increasing numbers of first degree relatives affected: RR = 1.8, 2.93 and 3.9 for 1, 2 
and 3 or more affected first degree relatives respectively(10).  This risk further increased if 
the relative was diagnosed with early onset breast cancer.  Once again these results 
17 
 
showed homogeneity across methodology, as regardless of how the study was carried out 
the results remained consistent, and when adjusted for various confounding factors.   
Family Member RR (95% CI) 
Any relative 1.9 (1.7-2.0) 
1st Degree Relative: 
All Ages 
<50 years 
≥50 years 
 
2.1 (2.0-2.2) 
2.3 (2.2-2.5) 
1.8 (1.6-2.0) 
Mother: 
All Ages 
<50 years 
≥50 years 
 
2.0 (1.8-2.1) 
2.0 (1.7-2.4) 
1.7 (1.5-2.0) 
Sister: 
All Ages 
<50 years 
≥50 years 
 
2.3 (2.1-2.4) 
2.7 (2.4-3.2) 
2.0 (1.7-2.4) 
Mother and Sister 3.6 (2.5-5.0) 
2nd Degree Relative 1.5 (1.4-1.6) 
Table 1.1 - A summary of the results of the meta-analysis performed by Pharoah et al (9), demonstrating the 
pooled estimated relative risk associated with each family member affected by cancer.  These results also 
highlight that the younger that a relative is affected then the greater the risk. 
 
The Nurses’ Health Study was in agreement with the two above larger studies(11) and also 
highlighted that age had a large influence on risk.  Those with a mother affected <40 years 
had a relative risk of 2.1 and if the mother was affected when she >70 years women had a 
far lower relative risk of 1.5. 
Family history is key in predicting risk and a recent paper has suggested that in clinical 
practice, family history is a better predictive tool for breast cancer risk than the Gail 
model(12).  This is reflected in the approach taken by the UK NICE guidelines, which 
emphasises the importance of family history when assessing a woman’s risk of breast 
cancer and therefore identifying the most appropriate screening pathway(13).  Family 
history is an established breast cancer risk factor which includes a large genetic component 
of the disease.  Breast cancer genetics are very heterogeneous and there are a large 
number of genetic factors which can contribute to an individuals’ risk of the disease.     
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3. Highly Penetrant Autosomal Dominant Breast Cancer Genes  
As demonstrated by the epidemiological evidence above, breast cancer risk is increased 
when family members have been affected by the disease - especially if the cancer was early 
onset.  It has been estimated that 10% of breast cancer cases are clustered within 
families(14).  Due to this apparent inheritance of breast cancer, researchers began to look 
for the genetic basis of breast cancer in these families.  To date they have found a number 
of genes which are linked to familial breast cancer; however the two genes which account 
for the highest proportion of inherited breast cancers are breast cancer 1, early onset 
(BRCA1) and breast cancer 2, early onset (BRCA2).  Other genes have been identified to 
increase the risk of breast cancers about 2 fold; for example CHEK2 and ATM(15).  However 
there are also a number of lower penetrance genes which contribute to risks in these 
families and in sporadic breast cancer cases too.   
Throughout this chapter the current literature on the genes involved in the inheritance of 
familial breast cancer shall be reviewed, to provide a short summary of what is currently 
understood about the higher penetrance genes and their encoded proteins.   
3.1 BRCA1 and BRCA 2 
BRCA1 and BRCA2 where first identified in the 1990’s (16–18) through linkage studies in 
large breast cancer families.  BRCA1 was initially identified by Hall et al, on chromosome 17, 
who looked at 23 families with 146 cases of early onset familial breast cancer(16).  BRCA2 
was identified 4 years later on chromosome 13 by Wooster et al(17).  Germ-line mutations 
in these two genes are thought to account for 15-20% of familial breast cancers(19), but 
there is still a great deal unknown about breast cancer genetics.  BRCA1 and BRCA2 are 
responsible for autosomal dominant breast cancer inheritance, and both genes are about 
80% penetrant by 70 years of age(20).  It is also important to note that BRCA1 and 2 both 
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also predispose to ovarian cancer, and increase the risk of prostatic, pancreatic, stomach 
cancer and melanoma(21).  
In the Ashkenazi Jewish population there is a higher rate of both BRCA1 and BRCA2 
mutations.  A single mutation (185delAG) of BRCA1 is responsible for 20% of early onset 
breast cancer in this population.  A further 8% of early onset disease is due to a specific 
deletion in the BRCA2 gene(22).   
Women with sporadic cancers are also commonly found to have somatic mutations and 
altered expression of BRCA1 and BRCA2(14), which is also common in ovarian cancer.  
Some women with germ-line mutations in these genes have also undergone a second 
somatic mutation, which causes the loss of wild type allele expression in the 
tumour(14,21).  Once again there is ongoing research into the implications of these somatic 
mutations in both BRCA carriers and sporadic cases, but their significance in terms of risk or 
potential therapies is still unclear. 
The proteins encoded by BRCA1 and BRCA2 can be thought of as caretakers, their function 
is to ensure that cellular stabilisation processes are working correctly.  Loss in their function 
can lead to instability and mutations in gatekeeper genes which causes the loss of normal 
cellular controls(14).  Both genes function within DNA damage repair pathways and are also 
commonly thought of as tumour suppressor genes(21).   
They are involved in the recognition and repair of double strand DNA damage via 
homologous recombination(21).  Double stranded breaks are more complex to repair due 
to the lack of complementary strand to use as a template, so choosing the correct repair 
pathway is critical(23).  The process of homologous recombination takes place during the S 
and G2 phase of the cell cycle, when the sister chromatids are available to use as a 
template(23).  The protein encoded by RAD51 is essential for this process and co-localises 
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with both BRCA1 and BRCA2 proteins.  However the roles of BRCA1 and BRCA2 within this 
pathway differ.  BRCA2 binds directly with RAD51 recombinase, and is thought to be 
involved in transporting RAD51 to damaged areas of DNA(23).  Whereas BRCA1 is known to 
be needed for homologous recombination, but relatively little remains known about how 
or why it is needed(14).  BRCA1 protein is also known to co-localise with RAD51 but not 
bind, however the significance of this is unknown(24).   
Genes mutated in Fanconi’s anaemia are also part of this repair pathway providing a link 
between it and the BRCA mutations(25).  Fanconi’s anaemia is an autosomal recessive 
disease with 13 different subtypes, which can be caused by mutations in 12 different 
genes(26).  A biallelic mutation in the BRCA2 gene can cause a subtype of Fanconi’s 
anaemia called FA-D1, which is one of the few associated with childhood solid tumours.  
Other genes associated with familial breast cancer including PALB2, which shall be 
discussed later, are also involved in the inheritance of Fanconi’s anaemia(26).  It is clear 
that a common pathway is involved however the relevance of this is as yet unknown.  
However it may provide avenues of research in terms of further elucidating breast cancer 
genetics, which has been a difficult field of research due to its heterogeneity.   
Double strand repair and chromosomal stability are linked, as without correct repair the 
chromosome losses stability(14).  It is therefore logical that BRCA1 and BRCA2 proteins are 
thought to both play a role in the stability of the chromosome throughout the cell 
cycle(27).  Loss of this stability is hypothesised to cause translocations, large duplications 
and fusions during the normal process of cell division(27).  These are all processes which 
have been linked to carcinogenesis. 
One of the BRCA1 proteins binding partners is BARD1 (BRCA1-associated RING domain 
protein) together they form a heterodimer, which functions as an ubiquitin ligase.  This 
complex plays a role in DNA repair, centrosome regulation and transcription.  The BRCA1 
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protein binds to a gamma tubulin which is part of the centrosome and its ubiquitin ligase 
activity is thought to prevent the centrosome from being overactive(28).  
More recently BRCA1 has been linked to a role in autophagy, which is the process by which 
organelles and proteins are degraded.  It is still unknown how the BRCA1 protein regulates 
autophagy, but when its protein expression is decreased autophagy is promoted(29).  This 
promotion of autophagy has been shown to have a function in malignant progression and 
autophagy markers are high in breast cancer(29). 
An additional essential role which both gene products have is in the regulation of the cell 
cycle, but once again the two differ in the exact nature of this role.  BRCA1 protein is a 
regulator of the G2-M phase of the cycle(23), which is the transition from chromosomal 
duplication to mitosis.  Whereas BRCA2 protein relates more to the progression through 
mitosis and the M phase check point(23).  Their involvement in the cell cycle once again 
relates to chromosomal stability and genomic integrity of the cellular contents, so if this 
process goes wrong it is likely there will be an increased instability and an increase in 
genetic mutations.   
The functions of BRCA1 and BRCA2 are complex and there is still much to be learned which 
could influence clinical management of patients in the future.  Some important questions 
which remain to be answered include: why do these ubiquitously expressed proteins 
promote breast and ovarian cancer?  And are these high penetrance genes influenced by 
the low penetrance polymorphisms(19,30)?   
3.2 Other Potential Candidate Genes 
BRCA1 and BRCA2 were the first identified and best studied familial breast cancer genes, 
however they only account for 15-20% of familial risk(14,19).  This therefore means there is 
a great deal still unknown about the inheritance of familial breast cancer.  This has led to a 
large amount of genetic analyses to find other genes which are associated with breast 
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cancer risk in these high risk families; however due to the heterogeneous nature of breast 
cancer genetics identifying other high risk genes like BRCA1 and 2 has been extremely 
difficult.  Despite these difficulties over the last two decades there have been a number of 
genes shown to increase breast cancer risk – these include PTEN, TP53, PALB2, ATM and 
CHEK2.   
The PTEN gene encodes a phosphatase and tensin homolog protein which acts as a tumour 
suppressor.  Mutations in this gene cause the autosomal dominant cancer predisposition 
syndrome Cowdens disease.  This predisposes affected individuals to thyroid, breast and 
skin cancer(31,32).  There is increasing evidence that germ-line mutations in PTEN may also 
predispose to non-Cowdens disease related high risk familial breast cancer(31).  This is a 
high risk gene which has a differing effect depending on the specific mutation, but which is 
a rare breast cancer predisposition gene. 
A second high risk breast cancer risk gene is TP53 which encodes the tumour suppressor 
gene p53, which is also associated with a rare cancer predisposition syndrome - Li-
Fraumeni Syndrome(2).  p53 is involved in cell transformation, cell cycle check-points, DNA 
repair and mediated apoptosis(33).  Various studies have associated a number of germ-line 
mutations with familial breast cancer risk and one paper estimated that 1% of inherited 
breast cancers have a germ-line TP53 mutation(33).  Additionally mutations in this gene 
seem to be an early event in sporadic breast tumourigenesis, and p53 expression is altered 
in 20-40% of sporadic breast cancer(34).  TP53 is a gene that is central to the predisposition 
of disease and is also involved in the progression of sporadic disease.  However as these 
mutations are rare TP53 accounts for a small proportion of high risk disease.   
The second set of genes involved in familial breast cancer are all associated with a 
moderate risk of breast cancer, causing approximately a 2 fold increase in risk(2).  PALB2 
(partner and localiser of BRCA2) is thought to infer a higher risk, up to an 8-9 fold increase 
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in risk, than the other genes discussed in this section(35).  It encodes a protein which co-
localises with BRCA2 and may function as a tumour suppressor(36).  It is thought to 
function in the same DNA repair pathway as BRCA2, a hypothesis which is supported by the 
fact that BRCA2 and PALB2 mutations have the similar breast cancer phenotypes(2). 
Additionally both BRCA2 and PALB2 are both mutated in different subtypes of the 
autosomal recessive condition Fanconi’s anaemia.  The subtypes they are associated with 
FA-D1 and FA-N, respectively, are also associated with a risk of solid tumours in childhood 
and function downstream of the FANCD2 complex(26). 
PALB2 mutations have been associated with an increase in breast cancer risk in small but 
substantial number of breast cancer families(37); one study has estimated that the 
prevalence was 1% in an a group of Australian women with triple negative breast 
cancers(36).  Mono-allelic mutations in PALB2 have been found to confer a 2 fold increase 
in risk in breast cancer families(26,36).  There has also been indications that PALB2 
mutations predispose to an early onset breast cancer opposed to a late onset phenotype; 
the relative risk of breast cancer <50 years old was 3.0 and 1.9 for over 50’s(26).  These 
results have been confirmed in a group of 362 people from 154 families; which found an 8-
9 fold increase in risk in those younger than 40 years old, 6-8 fold increase in risk in those 
40 to 60 years old and 5 fold increase in risk in those over 60 years old(35). There is clear 
evidence that mutations in PALB2 has an impact on familial breast cancer, but it is still 
unknown if mutations in this gene alone is enough to cause multiple breast cancer cases in 
one family.  
CHEK2 (Checkpoint kinase 2) encodes a cell cycle regulator, which has also been associated 
with a two fold increase in breast cancer risk(38,39).  This gene was first associated with 
breast cancer in a linkage study of a large breast cancer family(2), however mutations in 
CHEK2 are rare and only found in a small proportion of breast cancer families(38).  
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Mutations in this gene are thought to have a 4-5% prevalence in familial breast cancer 
cases, and the prevalence is thought to increase as the number of cases within the family 
increases(40–42). 
The protein encoded by CHEK2 is, as mentioned above, a check point regulator which 
phosphorylates the tumour suppressor p53 and BRCA1 both of which have been previously 
associated with familial breast cancer.  Phosphorylation of these proteins modulates the 
function of p53 to arrest the cell cycle in response to DNA damage(43).  Once again there is 
some uncertainty if a mutation in this gene alone could account for the clustering in 
families or if other mutations must also co-exist.  Additionally as with TP53, CHEK2 is also 
associated with the cancer predisposition syndrome Li—Fraumeni syndrome(43). 
ATM (Ataxia Telangiectasia Mutated) encodes a protein required for the activation of 
CHEK2 protein and other check point proteins in response to ionising radiation(41).  This 
gene was initially chosen for investigation because it had been noted that suffers of the 
rare neurological genetic condition Ataxia Telangiectasia and carriers had higher rates of 
breast cancer(44,45). 
Heterozygous carriers of certain ATM mutations are thought to present with a  2-4 fold 
increase in breast cancer risk, additionally there is no difference in risk between women 
under and over 50 years old(46,47).  This is a higher increase in risk than CHEK2, it is 
thought that the specific mutation in the ATM gene may influence the level of risk 
conferred by the mutated allele.  For example one study found two particular mutations 
which were 60% penetrant by 70years old, which is equivalent to a 15 fold increase in 
risk(48) this is far greater than the 2-4 fold risk increase predicted by other studies.   
All of the genes that have been discussed play a role in breast cancer genetics, and confer a 
moderate to high risk of developing breast cancer.  It is interesting to note that these five 
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genes converge in a common DNA repair pathway with BRCA1 and BRCA2.  However 
together BRCA1, BRCA2, PTEN, TP53, PALB2, CHEK2 and ATM probably only account for 20-
25% of inherited breast cancer risk, therefore there are still a number of genes yet to be 
identified.  These unidentified genes are likely to be a mixture of both highly penetrant 
genes and low penetrance polymorphisms.  Additionally the search for more candidate risk 
genes could potentially be centred on genes which also sit within this common DNA repair 
pathway. 
4. Low Penetrance Polymorphisms and Breast Cancer Risk 
Due to the recent emergence of genome wide association studies (GWAS) there have been 
a number of studies which have identified low penetrance polymorphisms associated with 
breast cancer (Table 1.2).  These are not directly causative of breast cancer but do increase 
an individual’s risk of developing the disease.  For example women with 14 of the 18 the 
risk alleles have a 6 fold increased risk of developing breast cancer compared to a woman 
with none of the risk alleles(49).   This polygenic model of breast cancer risk suggests that 
multiple low risk variants have an additive effect, which may eventually reach a threshold 
of disease when added with environmental and lifestyle risk factors(50).  These single 
nucleotide polymorphisms (SNPs) are believed to be responsible for 8% of excess familial 
risk(51). 
There is currently little known about how these small genetic changes predispose women 
to the development of breast cancer. It is thought that these changes perhaps subtly alter a 
proteins function or alter interactions within specific pathways(52).  Below is a summary of 
the loci in which breast cancer related polymorphisms have been identified (Table 1.2).  For 
each of these loci there have been candidate genes identified, which are thought to be the 
most likely gene responsible for the effect on risk.  However there is also a possibility that 
these genes may not be the reason for the alteration in risk seen, there may be other 
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genetics elements influencing breast cancer risk. For example within these regions of DNA 
there may be regulatory regions such as an enhancer or silencer which can be several 
hundred kilobase pairs from the promoter region.  Or additionally there are locus control 
regions which are groups of control elements that can regulate the transcription of genes 
involved in tissue specific expression.  These are just some of the transcriptional control 
elements which flank genes and could be alternatives to the genes identified as being 
involved in breast cancer risk(53).   
Of these candidate genes there is relatively little known about why they may be associated 
with breast cancer.  Therefore each of these polymorphisms which lie within a gene, or 
with a candidate gene, shall be discussed in turn with regards to their function and possible 
association within breast cancer.    
Gene  Locus SNP Identifiers Per Allele OR Source 
FGFR2 10q26 rs2981582 1.26  Easton et al 2007(54) 
TNRC9 (TOX3) 16q12 rs12443621 1.11  Easton et al 2007
 
(54) 
 5p12 rs4415084 1.19 Stacey et al 2008(55) 
NOTCH2 1p11 rs11249433 1.16 Thomas et al 2009(56) 
ZNF365 10q21 rs10995190 0.86 Turnbull et al 2010
 
(57) 
RAD51L 14q24 rs999737 0.94 Thomas et al 2009(56) 
ESR1 6q25 rs2046210 1.36 Zheng et al 2009
 
(58) 
 11q13 rs614367 1.15 Turnbull et al 2010
 
(57) 
CASP8 2q33 rs1045485 0.89 Cox et al 2007
 
(59) 
  2q35 rs13387042 1.12 Milne et al 2009
 
(60) 
NEK10, SLC4A7 3p24 rs4973768 1.11 Ahmed et al 2009(61) 
MAP3K1 5q11 rs889312 1.13  Easton et al 2007(54) 
CDKN2A/B 9p21 rs1011970 1.07 Turnbull et al 2010(57) 
 8q24 rs132281615 1.08 Easton et al 2007(54) 
LSP1 11p15 rs3817198 1.07  Easton et al 2007(54) 
 10q22 rs704010 1.07 Turnbull et al 2010(57) 
 10p15 rs2380205 0.94 Turnbull et al 2010(57)  
COX11 17q rs6504950 0.95 Ahmed et al 2009
 
(61) 
Table1.2 Summary of the low penetrance polymorphisms involved in breast cancer risk 
4.1 Fibroblast Growth Factor Receptor 2 
Fibroblast Growth Factor Receptor 2 (FGFR2 – located on 10q26) is the most strongly 
associated susceptibility locus for breast cancer(62); there is a 2 fold increase in risk in 
women homozygous for one particular single nucleotide polymorphism (SNP) in 
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comparison to those homozygous for the wild type allele(63).  To date there have been 5 
different SNPs in FGFR2 intron 2 associated with an increased risk of breast 
cancer(54,64,65).   
FGFR2 is part of the fibroblast growth factor family, which includes 22 fibroblast growth 
factors and 4 tyrosine kinase receptors.  These receptors, including FGFR2, are activated by 
the binding of a fibroblast growth factor (FGF) and heparin/heparin sulphate proteogylcan 
(HSPG) to the receptor which causes dimerization and autophosphorylation, followed by 
the activation of an appropriate signalling cascade.  These signalling cascades include the 
ras-MAPK pathway and the IP3 or DAG pathways(66).    
The FGF family of signalling factors are involved in embryonic development (cell 
proliferation, differentiation and migration), adult tissue homeostasis (tissue repair, wound 
healing and angiogenesis)(66) and mammary gland development(7).   
FGFR2 itself exists in two differing isoforms, b and c, which differ in their alternative 
splicing of exons 9 and 10(67).  These differing isoforms have different binding partners and 
expression patterns – FGFR2 b is expressed in endothelial cells and FGFR2 c is found in 
mesenchymal cells(66).   
Alterations in the FGFR2 gene have been associated with a number of cancers  including 
breast cancer, gastric cancer, lung and ovarian cancer(67).  It has also been found to be 
overexpressed in 10-15% of breast tumours(7).  Several studies have found that the 
rs2981578 SNP in FGFR2 intron 2 is associated with oestrogen receptor positive (ER) 
tumours(7,64) and there is also a small body of evidence indicating that this SNP is also 
associated with PR positive tumours(68).  This is suggestive that specific genetic risk factors 
may predispose to certain tumour characteristics or breast cancer subtypes.   
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There have also been some studies into interactions between FGFR2 polymorphisms and 
other modifiable risk factors such as smoking or alcohol consumption.  One example of 
such a study was carried out by Marian et al (2011)(64),  they investigated the relationships 
between the FGFR2 gene and smoking, alcohol consumption and obesity in breast cancer.  
No associations were found between FGFR2 and obesity or alcohol consumption, but there 
was a correlation between FGFR2 and smoking.  This study found a 2 fold increase in risk in 
smokers with the FGFR2 polymorphism in comparison to non-smokers.  However the 
authors do state that there may have been a short fall in their statistical power due to a 
small number of non-smoking controls.  Having said this it is an interesting finding that 
would be exciting to pursue further as it may elucidate the mechanisms by which FGFR2 
confers risk. 
There is still little understood about how the FGFR2 polymorphisms are involved in breast 
cancer pathogenesis, however there are some indications it could be related to differential 
levels of expression and hormonal pathways(7).  This is supported by the association with 
ER positive tumours and the elevated levels of FGFR2 expression seen in 10-15% of breast 
tumours.  Intron 2 has also been found to be highly conserved in mammals and is thought 
to have a number of transcription factor binding sites, some of which lie relatively close to 
the SNPs identified by GWAS(54).  Alterations at these transcription factor binding sites 
may represent the mechanism by which expression is altered in women with particular 
SNPs. 
4.2 Trinucleotide Repeat Containing Gene 9 
Trinucleotide repeat containing gene 9 (TNRC9) is otherwise known as TOX3 was identified 
by Easton et al (2007)(54), which has since been replicated by other groups in different 
populations(7,69,70).  It is hypothesised to be a transcription factor due to the presence of 
a high mobility group (HMG)(54). 
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When this loci was examined in a Dutch cohort for clinical correlations there was 
indications that it may be associated with younger age of diagnosis(71).  Studies have also 
linked TNRC9 with 3-4% increase breast density(72), which is an established breast cancer 
risk factor as discussed later.  Several other polymorphisms have also been marginally 
associated with an increase in breast density including LSP1, MAP3K1(73) and ZNF365(74).  
LSP1 and MAP3K1 have been estimated to account for 1.5% variation in breast density(73) 
and ZNF365 is thought to account for 0.5% of variation(74). 
However despite these associations with clinical factors there is very little understood 
about what the protein encoded by TNRC9 actually does.  In the brain TNRC9 protein has 
been shown to be involved in calcium dependent transcription(75).  This transcription has 
been shown to be essential for cell survival in neurones and TNRC9 is thought to encode a 
neuronal survival factor(76).  It has also been shown to be expressed in high levels in the 
central nervous system but is not normally expressed in breast tissue(76).  It is still unclear 
what the implications of these finding have on the role of TNRC9’s in breast cancer risk.  
However it will be interesting to see if there is TNRC9 expression in breast tumours and if 
could potentially play a role in tumour cell survival.   
4.3 5p12 
This locus was identified by Stacey et al in 2008, and there is only one gene in this interval 
which is a candidate for altering breast cancer risk.  This is programmed cell death protein 9 
(PDCD9 aka MRP530) which is a small mitochondrial subunit thought to be involved in pro-
apoptotic events(55,77).  The authors chose to look at this gene in particular as it had be 
identified in several previous GWAS studies but had never reached statistical significance.  
PDCD9 is not normally expressed in luminal epithelial cells, but has been shown to be up 
regulated in infiltrating ductal breast cancers(55).   
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However it is still unknown if this polymorphism relates to PDCD9, and if the risk is 
associated with this gene the mechanism underlying this relationship.  It may relate to its 
pro-apoptotic effects, and the polymorphism may make cells more resistant to apoptotic 
processes.   
4.4 NOTCH 2 
NOTCH 2 has been associated with breast cancer in several GWAS studies(56,78); one of 
these studies found that NOTCH2 polymorphisms where associated with ER positive 
tumours(78).  NOTCH2 is one of a family of transmembrane receptors which interacts with 
the membrane bound ligands Jagged 1, Jagged 2 and Delta 1.  Upon binding there is a 
cleavage event releasing a NOTCH intracellular domain which enters the nucleus to 
influence the expression of target genes(78). This NOTCH signalling plays a key role in 
neurodevelopment and cell fate decisions. 
NOTCH 1 and 4 have already been shown to be overexpressed in some breast cancers(79).  
So it is conceivable that there is a role for NOTCH 2 polymorphisms in the pathogenesis of 
some breast cancers. 
4.5 Zinc Finger Protein 365 
Zinc Finger Protein 365 (ZNF365) was first discovered to be associated with breast cancer 
risk in 2010 by Turnbull et al(57).  This particular zinc finger protein is also known as Su48, 
which has also been identified as a centrosomal protein.  This 407 amino acid polypeptide 
co-localises with the centrosome throughout the cell cycle. In a series of experiments in 
which the expression of ZNF365 was altered, it was found that it played an essential role in 
mitosis(80).  This role in mitosis may offer a mechanism by which a polymorphism in this 
gene could cause an alteration in the risk of breast cancer. 
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On another note, an alternative polymorphism in intron 4 of ZNF365 has been shown to be 
associated with a decreased mammographic density.  This could be thought of as a 
protective polymorphism as an increased density increases breast cancer risk - >75% dense 
tissue has a 4 to 5 fold increase in breast cancer risk(74).  Further research would be 
needed to identify if different polymorphisms in this gene could increase breast density.  
There is clearly a complex relationship between breast cancer risk and ZNF365, as different 
polymorphisms can both infer an increased or decreased risk.   
4.6 RAD51 Homolog B 
RAD51 Homolog B (RAD51L1) was identified by Thomas et al by a 3 stage GWAS study and 
is a member of the RAD51 protein family involved in DNA repair(56).  It encodes one of the 
5 paralogs of RAD51(51), which as mentioned above is involved in the repair of double 
strand breakages via homologous recombination.  RAD51L1 is not thought to directly 
interact with the damaged DNA itself but instead to play a role in junction processing 
during the process of homologous recombination(51).  In addition there has been a 
suggestion that its protein may play a role in cell cycle control and apoptosis as it has been 
shown to interact with p53(51). 
It has also been shown that like some of the other low penetrance polymorphisms there 
has been an association between polymorphisms in RAD51L1 and mammographic density, 
which is associated with risk(81).  However none of the SNPs in this gene have been 
associated with a specific subtype of breast cancer, it appears be associated with all 
tumour types including triple negative(82).   
This gene, like many other genes implicated in breast cancer risk, is involved in DNA repair 
pathways.  This highlights the importance of loss of genomic stability in the progression of 
breast carcinogenesis(51). 
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4.7 Oestrogen Receptor 1 
Oestrogen Receptor 1 is the most likely candidate gene identified in the locus found to be 
associated with breast cancer by Zheng et al(58).  The SNP lies 180Kbp upstream of the 
translation start site and 26kbp of the first untranslated exon.  Other genes in this area 
included PLEKHGI, MTHFDIL, AKAPI2, ZBTB2, RMNDI, C6orf211, C6orf98 and SYNE1(58).  
However due to the oestrogen receptors established role in breast cancer pathogenesis 
ESR1 has been pursued as the most likely gene to be involved in conferring an increased 
risk of breast cancer(58,83).  Other studies have reproduced similar results in the same 
locus in different study populations, further supporting a role for this region in breast 
cancer risk(84). 
The ESR1 gene codes for oestrogen receptor (ER) alpha which can be elevated in both pre-
malignant and malignant tumours, and is both a predictive and prognostic factor in terms 
of clinical management(83).  Upon activation the ER can regulate the transcription of target 
genes, which regulate the growth and differentiation of normal breast tissue(85).  There 
has also been some evidence that the ESR1 gene is amplified in a proportion of breast 
cancers(86), however the quoted values vary widely from 20%(87) to 5.9%(85,88).  There 
have also been indications that clusters of ESR1 accumulate in the nucleus in some 
tumours, which is not seen in normal breast tissue.  However the reason for this or its 
implications are as yet unknown(85,86).  It is also still unknown if there is any connection 
between this gene amplification and the polymorphism in the region of the ESR1 gene.  The 
exact mechanism by which ESR1 increases breast cancer risk, and indeed if the SNPs in this 
region actually relates to ESR1 opposed to another candidate gene remains unknown.  
4.8 Caspase 8  
Caspase 8 (CASP8) was identified as a gene in which polymorphisms have an impact on 
breast cancer risk(59) in a case control analysis by the breast cancer association 
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consortium.  One polymorphism was recognised to be protective against breast cancer -  it 
was a single amino acid change of aspartic acid to histidine(59). Additionally there have 
been CASP8 polymorphisms associated with increased risk of developing breast cancer(89). 
CASP8 encodes one of the initiating factors for apoptosis; it is a pro-enzyme which means 
that is activated by cleavage by a caspase activating complex.  In the case of caspase 8 the 
activating factor is DISC, and together these are both part of the extrinsic pathway of 
apoptosis.  The extrinsic pathway relies on a death receptor to remove unwanted or 
damaged cells(90).  There have also been suggestions that caspase 8 has other 
moonlighting functions out-with its role in apoptosis; these functions include roles in cell 
migration and cell matrix adhesion(91). 
There has been some work done to investigate how CASP8 variants may affect apoptotic 
processes and thus have some influence over an individual’s risk.  A study which looked at 
the effect of the polymorphism on caspase-8 activity in peripheral lymphocytes found that 
different alleles had different levels of activity and apoptosis.  It is therefore conceivable 
that these alleles alter breast cancer risk by altering caspase-8 activity and its apoptotic 
actions.  However further work on the subject is needed to confirm these results(89). 
4.9 NEK10 and SCL4A7 
At the locus 3p24 which was associated with breast cancer risk by Ahmed et al there were 
two plausible candidate genes suggested by the authors(61).  These were Never in mitosis 
related kinase 10 (NEK10) and solute carrier family 4, sodium bicarbonate co-transporter 
member 7 (SLC4A7) each of these shall be discussed in turn focusing on their mechanism of 
action and potential involvement in breast cancer risk. 
The NEK10 gene is part of a family of genes which control cell cycle but it is still unknown 
what its specific role is(61).  It encodes a serine/threonine protein kinase which has 
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recently been suggested to play a role in checkpoint control, more specifically the G2/M 
checkpoint.  However this work was all carried out in cell lines and further research will be 
needed to confirm its specific role(92).  NEK10 has also been implicated in other cancers 
including lung cancer(92).  Both its proposed function and a previous association with 
human cancer confirm this as a plausible gene to be involved in breast cancer risk. 
SLC4A7 on the other hand, encodes a bicarbonate co-transporter (61), which has been 
shown to be down regulated in 64% of tumours in a small case control sample(93).  This co-
transporter facilitates the movement of bicarbonate which controls intracellular and 
extracellular pH.  In tumour cells the intracellular pH tends to be more alkaline and the 
microenvironment more acidic (by approximately 0.2 pH)(93).  This relationship tends to be 
more pronounced in more aggressive cancers(94).  The difference in pH is thought to be 
due to a number of transporters including the one encoded by SLC4A7(94).  Currently the 
role of this transporter in controlling the pH of cells and the microenvironment in 
tumourigenesis is unknown, but this provides a plausible mechanism by which changes in 
this gene could increase breast cancer risk. 
It is still unclear which of these genes is responsible for the increased risk associated with 
3p24 locus identified by Ahmed and replicated by other groups(61,70,95).  However it can 
be seen that both have plausible mechanisms of action in terms of increasing breast cancer 
risk, but more research is needed to disentangle which gene is involved. 
4.10 Mitogen-activated Protein Kinase Kinase Kinase 1 
Easton et al(96) identified the SNP rs889312 in the MAP3K1 gene was associated with 
breast cancer in 2007.  Since there has been some evidence that MAP3K1 polymorphisms 
are associated with the oestrogen and progesterone receptor positive tumours(71). 
Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) is located on chromosome 
5q11.2 and encodes serine/threonine kinase.  It is part of the MAP kinase signalling 
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pathway that includes Ras, Raf, MEK and ERK, and is critical in cellular regulation(97).  Its 
mechanism of activation is by the process of autophosphorylation, but when 
phosphorylating other proteins MAP3K1 requires a magnesium co-factor(98).  
MAP3K1 is involved in the transcriptional control of some key genes which have been 
linked to tumourigenesis: c-Myc, c-Elk1, c-Jun and c-Fos.  This transcriptional control relates 
to the ability of MAP3K1 to activate MAPK2 via the process of phosphorylation.  Active 
MAPK2 then phosphorylates MAPK/ERK which trigger downstream signalling cascades to 
control transcription(99).  This signalling pathway has also been linked with HER2 receptor 
activity, another receptor which is up regulated in some breast cancers(99).  The MAP3K1 
pathway also converges with the FGFR2 signalling pathways, so having both polymorphisms 
may hypothetically have an effect on breast cancer risk.   Once again further work as to 
how this gene confers risk and its prevalence in the population is required to fully 
understand the impact of this polymorphism. 
4.11 Cyclin-Dependent Kinase Inhibitor 2 A/B 
Polymorphisms associated with breast cancer risk in cylcin-dependent kinase inhibitor 2 
A/B (CDKN2A/B) were discovered in 2010 by Turnbull et al(57).  There are 2 differing 
isoforms which is due to transcription of the first exon in one and not the other, hence the 
A/B.  The gene itself encodes a cell cycle regulator, which has previously been identified as 
a potential oncogene or tumour suppressor gene(100).  Very little is known about this gene 
in relation to breast cancer, but there are indications that like other breast cancer risk 
genes it is involved in cell cycle control; this once again highlights the convergence of these 
breast cancer risk genes within the same cellular processes and signalling pathways. 
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4.12 Lymphocyte Specific Protein 1 
Lymphocyte Specific Protein 1 (LSP1) encodes an intracellular F actin binding cytoskeleton 
protein which was associated with breast cancer risk by Easton et al(96).  This finding has 
been replicated in a large meta-analysis, which aimed to come to a conclusive decision on 
the relationship between this allele and breast cancer risk(101). 
The encoded F actin binding protein is expressed in lymphocytes and endothelial cells(50).  
It may be involved in neutrophil motility, cell adhesion and trans-endothelial 
migration(101). This function is thought to be guided by MAP kinase pathway and its 
normal function it thought to allow cells to travel to sites of injury. 
This gene has already been previously associated other malignancies including Hodgkins 
lymphoma and other haematological malignancies(50,102).  However its role in breast 
cancer is somewhat less clear, and further work will be needed to understand how 
polymorphisms in LSP1 could increase breast cancer risk. 
4.13 Cytochrome C Oxidase Assembly Protein 11 
Ahmed et al identified 17q23.2 as increasing the risk of breast cancer, the SNP lies within 
an intron of syntaxin binding protein 4.  STXBP4 is a novel insulin regulated syntaxin 4-
binding protein which directly interacts with p63 to stabilise ΔNp63 and is involved in 
glucose and GLUT4 vesicular transport(103).   
However Cytochrome C oxidase assembly protein (COX) 11 lies within close proximity to 
the SNP.  COX 11 encodes a protein which is responsible for the assembly of cytochrome c 
oxidase a crucial part of the respiratory complex(104).  Expression of COX11 was found to 
be increased in tumours and therefore has been taken forward as the candidate gene in 
this region, however the relationship between breast cancer and this polymorphism 
remains unclear(61). 
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There are numerous low penetrance polymorphisms which have been identified as playing 
a role in breast cancer susceptibility.  Polymorphisms which both increase and decrease risk 
have been identified within the same gene.  The genes implicated are across a wide variety 
of processes but there are one or two pathways which seem to be crucial.  These include 
DNA repair pathways, in particular homologous repair pathways, which is implicated by 
both high and low risk mutations.  The broad categories of processes which have been 
implicated by these SNPs are DNA repair, cell cycle, microenvironment, apoptosis, 
transcription and oestrogen signalling.  This begins to illustrate that the breast cancer 
polymorphisms tend to cluster in common broad processes, which are potentially involved 
in breast cancer pathogenesis.  This may begin to explain the additive effect having 
multiple polymorphisms has on risk.   
5. Summary 
Breast cancer genetics is extremely heterogeneous and still very little remains known 
despite the two decades of research since the discovery of BRCA1.  As previously stated a 
number of higher penetrance mutations have been identified in a number of breast cancer 
families, these include BRCA1, BRCA2, PTEN, TP53, CHEK2, ATM and PALB2.  There are also 
a variety of low risk polymorphisms which increase the risk of disease or susceptibility but 
are not causative.  These SNPs are spread across a variety of pathways and in general 
confer a small risk which will reach a threshold of disease when other risk factors are taken 
into account such as parity and lifestyle factors. 
There is also a tendency for the proteins encoded by these high and low risk genes to be 
involved in several common pathways including DNA repair, cell cycle control, and control 
of the microenvironment as demonstrated by Figure 1.1.   In addition to the convergence in 
functionality of these genes there are also indications that there may be interactions 
between these genes and other known risk factors.  For example a number of the low 
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penetrance polymorphisms have been associated with breast density (LSP1, TNRC9, 
MAP3K1 and ZNF365), a known risk factor which is covered in the following chapter.  The 
interactions between the genetic and environmental risk factors shall also be discussed in a 
later chapter.  This review of the genetic factors associated with breast cancer highlights 
two things: first that there are a vast number of diverse genes involved in the risk and 
pathogenesis of this disease.  Secondly that there are certain cellular processes and 
pathways which are common to these risk genes and interactions may exist between the 
genes themselves.   
  Cell Cycle 
  Apoptosis 
  DNA Repair 
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  Oestrogen 
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      Micro-
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Figure 1.1 A summary of the genes which have been identified as modifying breast cancer susceptibility 
and the broad biological processes which they are involved in.  This demonstrates that these genes are 
clustered within a few main cellular processes, which also that the proteins encoded by these genes 
interact with each other.  The blue double headed arrows indicate interactions between the genes 
themselves. 
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Reproductive Hormonal and 
Environmental Factors Which Alter 
Breast Cancer Risk 
1. Introduction 
The highest incidences of breast cancer worldwide are found in Western Europe and other 
developed countries, and the lowest incidence of the disease is in the Asian 
Subcontinent(3).  This differing incidence could be explained by a multitude of genetic and 
environmental factors.  However evidence from migration studies suggests that it is the 
influence of environmental factors which best explains this differing breast cancer 
incidence worldwide.  These studies show that the offspring of women from areas with a 
low incidence of breast cancer who have migrated to the USA, will have breast cancer rates 
the same as the US averages within a couple of generations(105).  This indicates that the 
environment has an influence on breast cancer risk in addition to the genetic risks 
discussed previously.   
Identification of these environmental risk factors contributing to breast cancer began in the 
1970’s.  These epidemiological studies have now identified a variety of risk factors which 
have a generally accepted association with breast cancer risk.  Some of the strongest 
associations have been between breast cancer and reproductive history and hormonal 
preparations.  Early age at menarche, late age at first full term pregnancy (FFTP) and 
menopause (4-9) have all been linked to an increased risk of developing breast cancer.  
Other factors such as breastfeeding and multiparity have been identified as being 
protective against the disease(112–115).  Prescribed hormonal preparations such as the 
oral contraceptive pill (OCP) and hormone replacement therapy (HRT) have also been 
associated with an increased risk of developing breast cancer(110,116–123). 
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Some potentially modifiable lifestyle factors and other environmental factors have also 
been investigated to determine their relationship with breast cancer risk; these include 
body mass index (BMI)(124–128), diet(129–138), smoking(139–143), alcohol 
consumption(139,144–147), ionising radiation exposure(148–151), ethnicity(119,152–154), 
socioeconomic status(155–157), mammographic density(158–164) and environmental 
exposure(165–170) to chemicals at work or in the home.  Of these factors age, BMI, 
radiation exposure, mammographic density and alcohol consumption have all been studied 
extensively and are generally accepted as being involved in breast cancer risk.  
To provide a comprehensive evaluation of environmental factors and breast cancer risk the 
evidence for the associations between a number of environmental and reproductive 
factors with breast cancer will be evaluated, including a brief description of the biological 
mechanisms believed to underlie this relationship.   
The literature search in this case shall be a journalistic review of the vast epidemiological 
literature on the subject.  The focus of the review shall be on larger meta-analyses, pooled 
analyses, systematic reviews, and larger cohort or case control based studies.  Suitable 
articles were identified via Medline searches using breast neoplasms – 
aetiology/epidemiology, with an appropriate accompanying MeSH search term (see 
Appendix 2).  The literature search was further expanded by exploring relevant papers 
within the references of the papers identified by the original Medline search.   
2. Reproductive and Hormonal Factors 
Ramizzini was the first to observe the link between a woman’s reproductive history and risk 
of breast cancer in the 1700’s.  He observed that the rate of breast malignancy was greater 
in group of Italian nuns in comparison to the general population(105).  This has continued 
be a popular subject of epidemiological study which has continued in recent years, and the 
consensus of this work is summarised below. 
41 
 
2.1 Age at Menarche and Menopause  
Early age of menarche and late age at menopause have generally been accepted as 
increasing an individual’s risk of developing breast cancer.  Pike’s theory of breast tissue 
ageing may help understand why these two reproductive events could influence the risk of 
developing breast cancer(171).  It states that breast tissue begins the process of “ageing” at 
menarche; “ageing” is defined as proliferation, and differentiation accompanied by the 
potential to accumulate genetic mutations.  This process is influenced by the levels of 
circulating reproductive hormones and continues until menopause.  The rate of the ageing 
process varies with time and reproductive events – the highest rate is between menarche 
and FFTP, and then drops to a lower constant rate.  During the peri-menopause this rate 
begins to decline again until menopause is reached (Figure 2.1).   
Pikes theory of breast tissue ageing is in alignment with the developmental process of 
breast tissue, which occurs between menarche and FFTP, and is also influenced by levels of 
circulating sex hormones.  After the first full-term pregnancy breast epithelium is fully 
differentiated, and at this stage is thought to be more resistant to carcinogens and the 
hormonal milieu of the breast(167).  These endogenous hormones include oestrogens and 
Age 
Rate of 
Tissue 
Ageing 
Menarche 
FFTP      
Peri-Menopause 
 
Menopause 
Figure 2.1:  Simplified diagram demonstrating Pike’s hypothesised pathway of breast tissue ageing.  This 
process is influenced by hormone levels and events in a woman’s reproductive life.  Increased tissue age is 
thought to relate to an increased number of potential neoplastic changes which could happen within the 
cells.  Adapted from Pike et al (1983)
 (65)
. 
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progesterones; both of which initiate proliferative and developmental activity within breast 
epithelial cells and are associated with breast cancer pathology(172).  Menarche and 
menopause mark the beginning and end of ovarian activity and a woman’s reproductive 
lifespan(173).  Therefore if ovarian activity begins earlier and ends later breast tissues are 
exposed to these endogenous steroid hormones for longer period of time(111). 
The association between early menarche and risk has been identified by various studies.  
One large meta-analysis by the Collaborative Group on Hormonal Factors in breast cancer 
(2012) looked at 117 studies from 35 different countries, which only included women who 
had never taken HRT.  It found that there was a relative risk of (RR) = 1.05 (CI 95% - 1.044 – 
1.057; p <0.0001) for every year younger than 13 years old a woman was at menarche 
(Figure 2.2).  However in postmenopausal women it was found that an increased current 
body mass index (BMI) removed the increased risk associated with menarche and 
menopause(173).   It is unknown why a high BMI attenuates this increased risk but it may 
relate to the mechanism by which a high BMI increases breast cancer risk in 
postmenopausal women, which is discussed in more detail later.   
Figure 2.2 - Relative risks of age at menarche and menopause as estimated by a large collaborative reanalysis, which 
illustrates that with decreasing age at menarche and increasing age at menopause there is an increased breast cancer risk.  
Adapted from The Collaborative Group on Hormonal Factors (173). 
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As part of the Women’s care study Li et al (2008), failed to find any association between 
age at menarche and breast cancer(108).  Instead they identified a higher breast cancer risk 
in women with a larger age gap between age at menarche and FFTP in both pre- and 
postmenopausal women.  For example in pre-menopausal white women who had a ≥16 
year gap between the two events had a 1.5 fold increased risk, when compared with those 
who had a gap of <5 years between menarche and FFTP.  These results must be interpreted 
with caution as there were small numbers of participants when they were divided into 
subgroups for analysis.  Additionally as with all case-control studies issues such recall and 
selection bias must be considered.  These results do fit with Pikes model as the longer the 
gap between menarche and FFTP the longer that breast tissue is at its maximal rate of 
tissue ageing.   Li et al did however publish an earlier study in 2007 in which they found an 
increased risk associated with earlier age of menarche (≤11yrs compared to ≥14yrs RR = 
1.3)(174).   
A smaller meta-analysis, only including 9 studies, found that an older age at menarche was 
protective against both oestrogen and progesterone receptor positive (ER+/PR+) tumours 
and negative (ER-/PR-) tumours(175).  These results will need to be replicated by further 
studies and some research will be require to identify biological significance of this is still 
finding.  The majority of the evidence supports a relationship between age at menarche 
and breast cancer risk, as being a small but significant effect on risk. 
Age at menopause is also an established breast cancer risk factor and some of the 
significant papers which established this are highlighted in a review by Parkin (2011)(111).  
One of these papers found that the risk of breast cancer was doubled in women who went 
through the menopause at age 55 years when compared women who went through it at 45 
years old or younger(176).  In 1996 the Collaborative Group on Hormonal Factors in Breast 
Cancer published a large re-analysis of 51 papers which found similar results to the above 
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study.  They found that for every year older a woman was at natural menopause there was  
2.9% (standard error (SE) 0.3) increase in breast cancer risk(118).  In these large re-analyses 
it is important to remember they may not lack statistical power, but due to the large 
variety of papers used there is a substantial likelihood of heterogeneity, due to differing 
methodologies and study populations.  A second paper by the same group published 2012 
found the RR =  1.029 (95% CI: 1.025-1.032; p<0.0001) with every year older at menopause 
(figure 2.2)(173).  This later paper suggested that the age at menarche seemed to have a 
larger effect on breast cancer risk than age at menopause.  It is still not known why this was 
the case.  
It is clear from the evidence above that the both the age at menarche and menopause can 
both contribute a small but significant increase in breast cancer risk.  The reason for this is 
thought to relate to the resistance of the breast tissue itself, exposure to endogenous 
hormones and the rate of hypothetical breast tissue ageing. 
2.2 Age at First Full Term Pregnancy and Parity  
Evidence suggests a later FFTP can increase the risk of breast cancer developing in later life, 
which may relate to the developmental stage of the breast tissue; as prior to pregnancy 
breast tissue is in an undifferentiated state and after the FFTP the breast tissue is fully 
differentiated.  When fully developed it is thought to be less sensitive to carcinogens and 
endogenous hormones(107).  The relationship between breast cancer and age at FFTP has 
been confirmed in a number of both animal and human studies(108). 
A prospective cohort study by Li et al (2007) discovered woman whose FFTP was at aged 35 
or older had a significantly increased risk when compared to those aged ≤19yrs at FFTP; RR 
= 2.0 (95% CI: 1.1-3.7; p = 0.01)(174).  This is in agreement with the results from the 
Californian Teachers Study, who found in their cohort with 10.5 years follow up women 
who were 35 years or older at FFTP had a 27% increased risk in comparison to those who 
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had their first child at 21 years or younger.  They also identified a significant trend for 
increasing risk with later age at FFTP (ptrend= 0.002)(113).   
Some research has shown that an earlier age at FFTP specifically protects against ER and PR 
positive cancers(175,177).  This is biologically plausible as an earlier FFTP will decrease 
exposure to endogenous sex hormones, but once again the specifics of this association 
remain unclear. 
Parity was first associated with breast cancer over 400 years ago by Ramizzini in a 
population of nuns, as mentioned above.  In recent years there have been formal 
epidemiological studies which have confirmed this relationship between parity and breast 
cancer risk; these have shown that higher parity is associated with a lower cancer risk.  It is 
important to note that the protective effects of parity and breastfeeding are very closely 
linked and they may have a confounding effect on one another, as it is hard to disentangle 
the two(115). The mechanism underlying this protective effect is not clearly understood 
but it has been suggested it may relate to decreased levels of circulating oestrogens and 
progesterone.  Additionally there is thought to be increased amounts of sex hormone 
binding globulin (SHBG) and therefore less free oestrogens, as well as an increase in human 
chorionic gonadotropin (hCG)(113). 
A collaborative analysis which studied women who never breastfed from 47 studies, found 
that with each birth there was a significant reduction in breast cancer risk by 7% (SE 1.0%; 
p<0.0001)(115).  The reduced risk with increased parity was observed regardless of 
ethnicity, age or country of origin.  This reanalysis has two major strengths firstly its large 
number of participants and secondly that it controlled for breast feeding.   
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In general it has been found that having children is protective in comparison to being 
nulliparous (RR = 0.91), irrespective of number of children (113).  There has also been an a 
trend for decreasing risk with increasing numbers of children identified (Ptrend = 0.003)(113).   
There is some evidence that this protective effect is lost with age.  For example in the Long 
Island Breast Cancer study cohort in women less than 65 years old parity was protective(OR 
= 0.7, 95% CI 0.48 -1.10).  An effect that was once again found to be stronger in those with 
more children (≥ 4 children OR = 0.48; 95% CI: 0.25-0.9).  However when women over the 
age of 65 were studied this protective effect was found to be statistically insignificant(106).  
When interpreting these results it is important to note that the effect of increasing age on 
risk may be confounding the protective effect of parity in these older women. 
A recent meta-analysis found an association between ER/PR positive tumours and parity – 
which found an 11% decrease in the risk of an ER+/PR+ tumour with each birth(175).  This 
relationship may relate to the relationship between breast cancer pathogenesis and 
endogenous hormone levels(177). 
Both young age at FFTP and multiparity convey a small but important protective effect 
against the development of breast cancer, which has been established by numerous large 
studies and meta-analyses.  These two factors may play a role in the increasing incidence of 
breast cancer in the developed world over the last 40 years.  As there have been a great 
deal of societal changes which have led to women having children later in life and many 
women choosing not to have children at all(3).  However nulliparity and late age at FFTP 
are not the sole contributors to this increased incidence and other factors are almost 
certainly involved.   
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2.3 Breastfeeding 
Breastfeeding has various benefits for mother and child, one of these benefits is that it is a 
potentially modifiable breast cancer risk factor.  However over the years there has been 
some inconsistency in the data on breastfeeding and breast cancer risk, with studies 
producing a wide range of results(115).  The inconsistency may in part be due to the 
problems caused when trying to separate it from parity.  There are several proposed 
mechanisms by which breastfeeding is thought to be protective including postponing 
ovulation, decreasing circulating oestrogens and progesterone, or increasing prolactin 
levels.  It may also initiate the terminal differentiation of the breast epithelium, therefore 
allowing the breast tissue to be more resistant to potential carcinogens.  Another proposed 
mechanism underlying this protective effect is the direct mechanical effect of the excretion 
of oestrogens and carcinogens during lactation(114). 
Breastfeeding was investigated in a prospective cohort of 60,075 parous pre-menopausal 
women by the Nurses’ Health Study (112).  The relative risk of women who had ever 
breastfed was 0.75 when compared to those who had never breastfed; these results 
remained unchanged when adjusted for age at FFTP and multiparity.  The length of time 
spent breastfeeding was not found to have any association with risk.  In women with an 
affected first degree relative the protective effect was significantly increased– RR = 0.41 
(95% CI: 0.22 – 0.75)(112).  Suggesting breastfeeding may have added protective benefits in 
women with a family history of breast cancer. 
However other studies have failed to reproduce these results, for example a study of 
breastfeeding in a Japanese population found that there was not enough evidence to 
support a protective effect(114); this was a systemic review which included 3 cohort 
studies and 5 case-control studies.  Individually these studies found a range of results from 
null findings to an inverse relationship and only looked at small numbers within a small 
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population - for example one in particular only had 3 controls who had never 
breastfed(114).  The above factors may have contributed to the inconclusive results of 
these individual studies and the systemic review.   
Other larger studies have found results corresponding to those of the Nurses’ Health Study, 
an example of one such study was a large re-analysis of 47 papers from 30 different 
countries(115).  This large re-analysis however also found a relationship between duration 
and parity; every 12 months of breastfeeding conferred a 4.3% significant decrease in risk.  
There was also a significant decrease in risk (3.4%) for each child breastfed, all these results 
remained the same when adjusted for country, age, ethnicity and childbearing pattern 
(115).   
A meta-analysis looking at the relationship between breastfeeding and tumour 
characteristics found that breastfeeding was associated with a decreased risk for both 
ER+/PR+ (RR = 0.95) and ER-/PR- cancers (RR = 0.91)(175).  Therefore it is possible that the 
protective effect of breastfeeding differed from that of multiparity and age at FFTP.  This is 
perhaps demonstrated by the number of different plausible mechanisms by which 
breastfeeding may exert its protective effect(177).   
The literature on breastfeeding and breast cancer does suggest it exerts a small protective 
effect, but there are inconsistencies as to whether number of children and duration of 
breastfeeding alters this protective effect.  There are many difficulties in getting a clear 
impression of the impact breastfeeding has on breast cancer due to the issues with data 
collection including recall bias and the difficulties disentangling breastfeeding from parity.  
2.4 Hormone Replacement Therapy and Hormonal Birth Control  
Prescribed hormonal preparations have been studied a great deal with respect to their 
effect on breast cancer risk.  Hormone replacement therapy (HRT) is a well-established and 
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generally accepted breast cancer risk factor.  The evidence as to whether hormonal birth 
control (HBC), including the oral contraceptive pill (OCP), contributes to breast cancer risk is 
less abundant, consistent and clear cut.  These prescribed hormonal preparations introduce 
exogenous oestrogens and progestogens which alter the hormonal milieu of breast tissue.  
They are therefore thought to have the potential to increase breast cancer risk, as these 
hormones increase proliferative and developmental activity within the breast tissue.  
Three large studies provided the basis for the association between breast cancer and HRT 
use -  these were the Women’s Health Initiative (WHI)(178–180), Collaborative re-
analysis(110) and the Million Women Study(117).  A double blinded oestrogen-
progestin/placebo randomised trial was performed by the WHI study with 16,608 post-
menopausal female participants, which aimed to assess the effect of HRT on cardiovascular 
and breast cancer risk over a period of 8.5 years follow up.  However the trial was stopped 
early after only 5.6 years due to a recommendation by safety board, as the risk of  
developing breast cancer was deemed to outweighed the benefit of the trial 
continuing(179,180).   This was because the safety limit of breast cancer occurrence among 
the group using HRT being reached.  A preliminary analysis of the results demonstrated 
that women taking combined HRT had relative risk of 1.24 of developing invasive breast 
cancer (weighted p = 0.003).  The publication of these results was accompanied by a global 
decrease in the use of HRT(181). 
In the same time period the MWS was published and consisted of data from a large UK 
cohort(117).  They found a 43% increase in breast cancer risk in women who had ever used 
HRT when compared to those who had never used HRT.  Current HRT users had a 66% 
increased breast cancer risk; however this increased risk was attenuated within 5 years of 
stopping therapy.  The MWS found the largest risk associated with the use of a combined 
preparation (RR = 2.00; 95% CI 1.88-2.12).   However the follow up on this study was 
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extremely short at only approximately 2.6 years, this could have led to an inaccurate 
calculation of risk.  This said the MWS did confirm the results of the WHI and the results of 
the MWS are summarised in Figure 2.3. 
Prior to both of these studies the Collaborative Group on Hormonal Factors in Breast 
Cancer published evidence that HRT use was associated with an increase in breast cancer 
risk(110).  They demonstrated that women who had ever used HRT had a 14% increase in 
breast cancer risk.  This increased risk was further increased with longer duration of use.  
Once again current users were demonstrated to be at the highest risk with a 22% increase 
in risk.  In agreement with the MWS, the Collaborative Group on hormonal factors 
demonstrated this excess risk was found be attenuated after 5 years of discontinuing HRT 
(5-9 years ago V.s. never RR = 1.01).   
Shapiro et al (2011)(182) have published a series of articles criticising these studies, 
questioning their methodological validity and the biological plausibility of HRT increasing 
breast cancer risk.  The authors claimed that the use of HRT by patients had declined 
unfairly due to the evidence published by the MWS, WHI and Collaborative reanalysis.  It is 
important to note that several of the authors involved in the critical analysis of these 
studies had all at one point been employed by pharmaceutical companies responsible for 
the manufacture of HRT.   
Figure 2.3 - Summary of the findings from the MWS (Adapted from the MWS -(116)).  The relative risk of HRT use is 
highest in current users and decreases to that of the population/never users within 5-9 years of discontinuing 
therapy. 
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However contrary to the claims of Shapiro et al there is epidemiological data 
demonstrating a decline in worldwide breast cancer incidence which coincides  with the 
decline in HRT use from 2002 (181).  It could therefore be assumed that the decrease in 
HRT use may be one of the contributing factors to this decrease in incidence.  For example 
in Germany the use of HRT declined by 50% between 2002-2005 and over the same period 
there was a 8.7% decrease in the incidence of breast cancer.  Similar trends were noted in 
other developed countries including France, Belgium, Australia, New Zealand and Canada.  
There are most certainly other factors which will have contributed to the decline in 
incidence,  however it is conceivable that a proportion of this decline is related to changes 
in HRT use(181).   
Various studies have come to differing conclusions as to whether HBC increases the risk of 
breast cancer.  In part this may be due to the various different hormonal preparations 
which are available and the changes in these preparations and their doses over time(120).  
Other factors could be also acting to confound the results as well including nulliparity, not 
breastfeeding, and age at FFTP – all of which are increased by the use of HBC.   
A combined analysis of 54 epidemiological studies investigated the relationship between 
the OCP and breast cancer found that current users had a 24% increase in risk (95% CI: 
1.15-1.33), which diminished to 7% (95% CI: 1.02 – 1.13) after 10 years of stopping use of 
the OCP.  This analysis failed to find a relationship between risk and the preparation of OCP 
used or duration of use(118).  These results have been replicated by a more recent study, 
showing current HBC use increases risk by 33% but they found no association between past 
HBC use and risk(121).   
A meta-analysis of case-control studies investigating the use of OCP among pre-
menopausal women concluded that ever using OCP caused a 19% increase in the risk of 
developing breast cancer(123).  Stratifying women into groups dependent on parity or 
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whether HBC was used before or after FFTP did not significantly alter the results.  It is 
important to note that the use of crude odds ratios due to the heterogeneity of the papers 
analysed may have led to an overestimation of risk by this analysis.  
A systemic review analysed a number of recent papers and concluded OCP may increase 
the risk of developing breast cancer, despite a number of studies which failed to find any 
association between the OCP and breast cancer(120).  There is some evidence that the use 
of the HBC could have a modest effect on breast cancer risk, however like HRT its effect is 
attenuated within 5-10 years of discontinuing treatment.  It does however remain unclear if 
the duration of use, preparation and age at exposure to HBC has any influence on breast 
cancer risk.  Trying to tease out this relationship may prove difficult due to the large 
number of preparations available, recall bias, and the issues disentangling it from the risk 
associated with parity and age at FFTP. 
There is a considerable body of evidence including some large pooled analyses supporting 
increased breast cancer risk associated with a range of reproductive factors:  including age 
at menarche, menopause and FFTP, parity, HRT and HBC use are generally accepted as 
contributing to breast cancer risk. 
3. BMI and Dietary Influence on Risk 
Despite the fact that BMI and diet are intrinsically linked, only BMI has been consistently 
associated with breast cancer risk.  There is less consistent evidence regarding the 
influence of diet on breast cancer risk.  This may in part be due to the issues caused by 
trying to quantify and record a person’s dietary intake, as well as the variation in diet 
worldwide.  
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3.1 Effect of BMI on Post-Menopausal Women 
Body mass index (BMI) is a 
measure of obesity, which is 
calculated by dividing an 
individuals’ weight in 
kilograms by their height in 
metres squared - (𝐵𝑀𝐼 =
𝑊𝑒𝑖𝑔ℎ𝑡 𝐾𝑔
𝐻𝑒𝑖𝑔ℎ𝑡 𝑚2
. The influence of 
BMI on breast cancer risk has 
been shown to differ 
dependent on menopausal 
status.  Post-menopausally a 
high BMI is associated with an 
increased risk of developing breast cancer.  The underlying biological mechanism relates to 
the conversion of androstenedione to estrone by adipose tissue in post-menopausal 
women to increase circulating levels of oestrogens.  In women with a high BMI there is 
more adipose tissue so a greater capacity to increase circulating oestrogens.  Obesity also 
decreases the levels of sex hormone binding globulin (SHBG).  Together the increased 
peripheral conversion and decreased SHBG result in an increase in circulating bio-available 
oestrogens (Figure 2.4)(124,172,183).  The use of HRT is thought to attenuate the effects of 
BMI on risk as it increases the circulating exogenous oestrogens far more than the level of 
endogenous oestrogen could be by the excess adipose tissue.  So a high BMI is thought only 
to increase risk in post-menopausal women who do not use HRT(172). 
There have been various different measures of obesity used across various different 
studies, and all have generally shown that obesity increases breast cancer risk in 
Androstenedione 
From postmenopausal ovaries and 
Adrenal glands.  
Estrone 
Total 
Estradiol 
Aromatase In  
Adipose Tissue 
17β 
Type 3 
17β 
Type 1 
Bio-unavailable  
SHBG bound – 30-50% 
Bio-available 
Albumin bound 
Free/unbound – 1-2% 
In obesity 
In obesity In obesity 
Figure 2.4 – This illustrates the oestrogen production pathway in 
postmenopausal women.  Adipose tissue is vitally important in the 
conversion of Androstenedione to Estrone.  The blue arrows denote 
any changes in homeostasis that are linked with obesity.  This shows 
the potential for an increase in bio-available oestrogens in 
postmenopausal women with a high BMI.  Adapted from Stephenson 
and Rose (2003)
 (66)
. 
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postmenopausal women. BMI provides a more consistent measurement, when compared 
to waist circumference and hip to waist ratio as accuracy depends to a greater extend on 
the person taking the measurements.  So for this reason BMI is often used as it seen as 
more reproducible despite having other problems(124,184).   
Postmenopausal women who have a BMI in the highest quartile have a 57% increase in risk 
of developing breast cancer, compared to those in the lowest quartile, according to data 
from the WEB study(126).  Lahmann et al replicated these results, finding women with 
BMI’s in the highest quartile had a 54% increase in breast cancer risk (Table 2.1)(185).  The 
use of HRT was found to attenuate this increase in risk; which is thought to be due to the 
endogenous hormone production being greater than the exogenous hormone in HRT, 
therefore the risk produced by HRT is no longer significant.  A significantly increased breast 
cancer risk in postmenopausal women who had never used HRT was found by the MWS, 
which found  women with a BMI >25kg/m2 had a RR = 1.4(128).  Another large study called 
the Pooling Project re-analysed data from a large number of published cohort studies(127) 
and found that postmenopausal women with a high weight that had not used HRT had a 
higher breast cancer risk. 
There has also been speculation as to whether weight gain has any influence on risk, and 
there have been several papers which have found an association between increased risk 
and weight gain from the age of 20 (126,185,186).  The conclusion of one such study was 
that for every 5kg of weight gained there is a 4% increase in breast cancer risk(126).  These 
results must be interpreted carefully as this increase in risk may just reflect these women 
having a higher BMI, and therefore the risk could be associated with being overweight or 
obese and not the weight gain. 
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Table 2.1 - Relative risk of breast cancer in 
postmenopausal women according to BMI.  
Adapted from the Malmo study, Lahmann et 
al (185). 
 
The evidence above supports a relationship between a high BMI and the risk of developing 
breast cancer in postmenopausal women who have never used HRT.  This is especially 
evident in women who fall into BMI categories which lie in the highest quartile (Table 2.1).  
However it seems this increased risk is completely diminished by the use of HRT, which is 
thought to relate to the levels of circulating exogenous and endogenous hormones. 
3.2 Effect of BMI in Pre-Menopausal Women 
However in premenopausal women the story is slightly more complicated with a number of 
studies reporting a decreased breast cancer risk in women with a high BMI.  The biological 
reason underlying this observed relationship is poorly understood.  It is thought that it 
perhaps relates to the irregular menstrual cycles associated with obesity; due to these 
irregular cycles these women will potentially have lower levels of circulating endogenous 
hormones(124), which are predominantly produced by the ovary during this stage of a 
woman’s life(172,183). Lower levels of circulating hormones will in turn have an effect on 
Pikes hypothetical tissue ageing process. So the lower levels of hormones may protect the 
breast tissue by slowing the accumulation of cellular changes associated with Pikes ageing 
process. 
Both the Pooling project(127) and the MWS(128) found a protective relationship between 
premenopausal obesity and breast cancer.  Research by the pooling project found the 
relative risk was 0.58 when pre-menopausal women >80kg were compared with those 
<60kg(127).  A borderline significant trend  (p = 0.05) for decreasing risk with increasing 
BMI (kg/m
2
)
3
 Multivariate-Adjusted RR (95% CI) 
<22 Reference 
22.0-23.8 1.05 (0.67 – 1.62) 
23.9 – 25.7 1.20 (0.78 – 1.85) 
25.8 – 28.5 1.31 (0.86 – 2.01) 
>28.5 1.54 (1.01 – 2.35) 
P trend 0.023 
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BMI was uncovered in premenopausal women by the MWS(128).  Current evidence 
indicates that a high BMI may be protective against breast cancer in premenopausal 
women, which is the opposite of what has been found in postmenopausal women.  
However further work is required to fully establish this relationship and to uncover the 
biological mechanism underlying it. 
3.3 Diabetes Mellitus  
A high BMI is closely associated with type two diabetes mellitus (DM) and recently 
evidence has emerged which suggests that type two DM is an independent risk factor for 
breast cancer in postmenopausal women(187,188).  A proposed mechanism responsible for 
this increased risk involves both a direct mitogenetic effect in the breast epithelium by 
insulin; and an indirect effect via the increasing the levels of bio-available oestrogens by 
lowering the levels of SHBG (see Figure 2.4)(172).   
A meta-analysis by Larsson et al (2007) which looked at 20 published papers supported the 
hypothesis that DM contributes to breast cancer risk; this study concluded that there was a 
20% increase in risk in women who had type 2 DM when compared to those who did 
not(188).  However some of the studies included did not distinguish between the two types 
of DM, which have very different pathological processes.  The fact that the majority of 
diabetes is type two may have meant that including both types lead to an underestimation 
of risk.  This is a relatively new area of breast cancer epidemiological research and in the 
coming years it will be interesting to see the results of ongoing research.   
3.4 Diet 
A large amount of research has been carried out to try and associate dietary factors with 
breast cancer risk, as this is a potentially modifiable risk factor which could be used 
preventatively and may provide the key to explaining observations made by migration 
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studies.  Various foodstuffs have been investigated including: soy intake, red meat intake, 
cooking methods, fat intake, fruit and vegetable intake, dairy and egg intake.  Diet may 
modify risk by various mechanisms including DNA repair, DNA adducts, detoxification, 
carcinogens and have effects on oestrogens(129). 
However there are major methodological issues associated with these studies as 
quantifying diet over a lifetime is an extremely difficult task to undertake.  Issues such as 
recall bias are highly problematic, as the majority of people are unlikely to remember their 
dietary intake over a long period of time.  Recall bias could be present in other studies but, 
events relating to reproductive history are major events in a woman’s life which are far 
more likely to be recalled and with greater accuracy.  In an attempt to overcome the issues 
of recall bias the Food Frequency Questionnaire (FFQ) and the 7 day diet diary (7DDD) are 
often used in this type of study.  The FFQ asks participants to give information on how 
often they consume particular foods with simple measures of portions; whereas the 7DDD 
requires participants to list everything they have ate and drank over a 7 day period(129).  
There are advantages and disadvantages to the use of both methods of quantification; 
however the FFQ is more commonly utilised as it is slightly simpler. 
Due to the lower incidence of breast cancer in Asia it has been suggested that the high soy 
content in the Asian diet may have a protective effect(138).  One meta-analysis of 18 
studies found some evidence in support of a protective role of high soy consumption 
against breast cancer in both pre- and post-menopausal women.  Both authors did 
however conceded that these results should be interpreted cautiously(138) because of the 
availability, quantity and heterogeneity (χ2 = 41.06; p = 0.002) of the available data.  There 
is currently not enough evidence to fully support a protective role for soy and soy products 
against breast cancer.  This may partly be due to difficulties in assessing soy intake, and the 
lack of large scale studies.   
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High intake of red meat is thought to increase breast cancer risk.   This is thought to be 
especially true if the red meat is cooked at a high heat as this may increase the number of 
polyaromatic hydrocarbons (PAH) and volatile chemicals which can be produced during 
cooking(130,134).  There has not been a consistent link established between risk and red 
meat; with some papers finding it increased risk (130,134) and others failing to find an 
association(131,132).  There is a lack of consistent evidence which associates any modest 
increase in breast cancer risk with a high red meat dietary content or how it is cooked. 
The consumption of a diet high in fruit and vegetables has been associated by some with a 
protective effect, which is thought to be due to their antioxidant properties.  Once again 
the evidence remains inconsistent and the relative risks vary widely between different 
studies. In some studies only high fruit consumption has been associated with a decreased 
risk(136).  Others have found small significant decreases in risk with high fruit and 
vegetable intake(135), but others failed to find a relationship(136,137).  There have been 
vast amounts of work done looking at the relationship between risk and red meat, fruit and 
vegetable intake; however this has failed to produce conclusive evidence that there is a 
relationship between these foodstuffs and breast cancer. This is may be in part due to 
difficulties with quantifying dietary intake, data collection and defining the best time frame 
to collect data in.  It is currently still unknown if a woman’s diet is more important during 
puberty, at menopause, or prior to FFTP in terms of breast cancer risk. 
It has also been suggested that dietary fat intake may elevate the endogenous oestrogen 
levels and therefore predispose to breast cancer(129).  Holmes et al (1999) failed to find a 
significant relationship between high fat diet and risk, but they identified that a low fat diet 
(<20% energy from fat) may be protective.  However finding women who consume a diet 
that low in fat is extremely rare, therefore finding enough participants to carry out a study 
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on this would be extremely challenging(133).  There have been multiple studies to date 
which have failed to find a relationship between the two(189,190). 
Evaluating all the information above there is not enough consistent evidence to suggest a 
link between any dietary factors and breast cancer risk.  This does not mean there is not an 
association between breast cancer and diet; the lack of relationship to date may relate to 
the methodological issues faced when carrying out this type of study.  Additionally the 
majority of studies fail to take into account BMI, which is intrinsically linked to diet and may 
be influencing the results of the above studies.   
4. Alcohol Consumption 
There is now a body of evidence which supports a moderate increase in breast cancer risk 
with alcohol intake.  The biological mechanism which is thought to underlie this is that a 
moderate alcohol intake can increase the levels of circulating oestrogens, due to either an 
increased secretion or decreased clearance(144).  This is supported by the results of 
Dorgan et al who carried out a blinded controlled feeding study.  Women who consumed 
15g of alcohol (approximately 2 UK units or 250ml glass of wine) or 30g (  3̴.5 units) of 
alcohol daily for 8 weeks - Dorgan et al found that this increased their serum estrone 
sulphate levels by 7.5% and 10.7% respectively(191).  A second proposed mechanism is 
that acetaldehyde, a product of alcohol metabolism, may induce the production of reactive 
oxygen species which can cause cellular damage (192). 
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Figure 2.5 - Relative risk of breast cancer increases with increasing alcohol consumption.  Adapted from 
Hamajima et al (139). 
A positive relationship between alcohol intake and breast cancer risk has been confirmed 
by a number of studies(139,144,192–194).  A large re-analysis of 53 papers concluded 
drinking 4-5.5 units (35-44g or half a bottle of wine) of alcohol daily causes a 32% increase 
in breast cancer risk.  Drinking over 45g daily further increased this risk by a further 14% to 
46% (Figure 2.5)(139).   A second smaller study found for an increase of 10g of alcohol a 
day there was an associated 9% increase in risk (95% CI: 1.04-1.13)(144).  However there is 
currently still no evidence to support that the type of alcoholic beverage influences 
risk(139,144,192).   
Even a moderate increase in alcohol intake (10g/d which is  ̴1 drink a day) is thought to 
increase breast cancer risk(194).  The mechanism which underlies this could relate to an 
increase in endogenous oestrogen, or an increase in reactive oxygen species.  There are 
issues with studying alcohol intake as participants tend to under report consumption and 
there is a poor public understanding of the unit.  These factors may mean that the risk is 
being under-estimated by current studies, and that the risk conferred by alcohol 
consumption could be greater than currently estimated. 
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5. Smoking and Environmental Pollutants 
5.1 Smoking 
A panel of experts assessed all the available evidence with regards to breast cancer and 
smoking concluded that there was sufficient evidence to link breast cancer and active 
smoking, but not passive exposure(143).  It is thought that the carcinogens in tobacco 
smoke may be transported by lipoproteins and stored in breast adipose tissue.  These 
compounds stored in this adipose tissue are later metabolised and activated(195).  
Metabolites of tobacco smoke have been found in breast fluid of smokers, which supports 
the above mechanism(196).  These active metabolites are thought to cause damage to the 
breast tissue and have carcinogenic effects.  
There have been a number of positive associations found(142,195–201), some null 
results(139,169,202,203) and some studies have shown an inverse relationship between 
breast cancer and smoking.  One of these papers found a 32% (95% CI: 1.10 – 1.57) 
increase in breast cancer risk in current smokers; and greater exposures to tobacco are 
associated with a higher breast cancer risk(196).  Many papers have suggested that this risk 
was also greater the younger the woman started smoking or if they began smoking before 
FFTP(142,169,195,196,199,201).  This may be because the breast tissue is undifferentiated 
prior to the FFTP, which means it is more sensitive to the effects of the chemicals release 
by cigarette smoke; this phenomenon has been confirmed in animal studies(169).  Trying to 
separate smoking at a young age and smoking for a long time is very difficult, but currently 
both are thought to be associated with risk(141,169,196–198). 
Genetics may modify the level of breast cancer risk associated with smoking, as N-acetyl 
transferase 2 and other proteins play a critical role in detoxifying the carcinogenic 
compounds released from tobacco smoke (140).  Individuals homozygous for a variant of 
the N-acetyl transferase (NAT) 2 gene are known as slow acetylators, and there is evidence 
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that these women are at a greater breast cancer risk if they smoke(140).  This is an on-
going area of research but it does highlight that the interaction between genes and the 
environment can alter risk. 
There is however less consistent evidence as to whether passive smoking has any 
relationship with breast cancer risk; however the reason for the lack of consistent evidence 
may relate to the difficulties in assessing passive smoke exposure(204).  Many people have 
chosen to assess passive smoking by assessing whether women have ever lived with a 
smoker – however at best this is a crude measure of cigarette smoke exposure as it does 
not take into account smoke exposure outside the home.  A Long Island study showed 
women who lived with a smoking partner for >326 months had an increased relative risk of 
2.10 (95% CI: 1.47 – 3.02)(205).  The authors of this paper conceded that despite this 
evidence there was still no strong evidence associating breast cancer and passive smoke 
exposure.  Other studies have failed to find a relationship between the two (RR = 0.9; 95% 
CI: 0.83 – 1.2)(201).   
As the evidence currently stands active smoking has been accepted as causing an increased 
risk of breast cancer.  However there is still some uncertainty as to whether a high BMI 
alters this association between active smoking and risk(206).  Additionally the strength of 
the association between the timing of active smoking and duration of active smoking have 
on breast cancer risk remains unknown, but separating the two for future studies will be 
difficult.   
There is not enough evidence to support a relationship between passive smoke exposure 
and breast cancer risk.  Some studies have found that passive smoking may influence 
breast cancer risk, but the majority of studies have found little to no association between 
breast cancer and passive smoking.  The reason for this lack of evidence may be due to the 
difficulties in quantifying passive smoke exposure.   
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5.2 Environmental Pollutants  
Exposure to various environmental pollutants has been widely investigated to determine if 
they are associated with breast cancer risk.  However, despite the vast amount of research 
in this field there has been no conclusive evidence linking the two.  Once again this lack of 
consistent evidence may relate to the difficulties of measure a persons’ lifetime exposure 
to an environmental pollutant.   
Breast cancer incidence has been demonstrated to be higher in industrialised and urban 
areas, which has led to a variety of studies looking at the contribution of air pollutants to 
breast cancer risk(167).  One such study was the WEB study (Western New York exposures 
and breast cancer), which used a surrogate marker of harmful atmospheric chemicals like 
PAH and benzene called total suspended particles (TSP)(167).  There was a non-significant 
trend towards increased risk with increased TSP exposure in pre-menopausal women who 
were exposed at menarche and post-menopausal women exposed at time of FFTP.  This 
study failed to explore the contribution of cumulative exposure to TSP to breast cancer risk.  
Other studies which used TSP or PAH exposure have also failed to find an association with 
breast cancer(207,208). 
Studies have investigated other exposures including one US study, which looked at the 
correlation between atmospheric nitric oxide and breast cancer incidence(165).  A 
correlation between the two was identified – and the states with the highest emissions had 
the highest breast cancer incidence(165).  However this did not take into account any other 
factors which contribute to breast cancer risk such as socioeconomic status, reproductive 
factors and ethnicity.  A second study replicated these results in a Canadian population 
finding that higher NO2 exposure correlated with increased breast cancer risk(166).  
Unfortunately this study used crude predictive measurements of exposure and some 
controls had other cancers, therefore these results need to be interpreted with caution. 
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It is thought these environmental pollutants may promote DNA damage, tumour growth 
and increase the susceptibility of tissues to undergo malignant transformation(209).  
Unfortunately there is still a lack of evidence to conclude that certain environmental 
exposures contribute to breast cancer risk; however there are indications that this may be 
the case and research is ongoing. 
6. Ionising Radiation 
Evidence from women exposed to therapeutic radiation (for example Hodgkin Lymphoma 
treatment) and Japanese atomic bomb survivors have established ionising radiation as a 
breast cancer risk factor(148).  Exposure to ionising radiation prior to the age of 20 is 
associated with the highest risk of developing breast cancer and displays dose dependent 
relationship(149). 
Zheng et al (2002) demonstrated that postmenopausal women exposed to therapeutic 
doses of radiation on 6 or more occasions had an increased breast cancer risk – odds ratio 
(OR) = 2.5.  If these women were exposed before their 20th birthday then they had a higher 
risk than those exposed aged 20 or older - < 20 yrs OR = 2.1; >20 years OR = 1.4(150).  This 
case control study failed to show any associations between diagnostic doses of radiation 
and breast cancer risk.  For example the risk of breast cancer in women who had had 12 or 
more mammograms compared to those who had less than 6 was not significantly different  
- OR = 0.9 (95% CI; 0.6 – 1.3)(150).  
The case control study by John et al is in agreement with this finding that women who had 
ever versus never experienced diagnostic radiation exposure had no increase in risk; OR = 
0.99 (95% CI; 0.88 – 1.11) - this result was consistent regardless of whether these women 
where high or population risk of developing breast cancer(210).  On the other hand any 
exposure to therapeutic doses of radiation has been associated with an increased risk in 
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comparison to women who have never had this type of medical radiation exposure; OR = 
1.72 (95% CI; 1.70 – 2.55)(210).   
The relationship between radiation exposure and breast cancer risk in BRCA 1/2 and p53 
mutation carriers is thought to differ as they do not have the ability to repair certain types 
of DNA damage, as discussed above, which may be caused by even small diagnostic doses 
of ionising radiation(211).  It is therefore believed that even diagnostic doses of ionising 
radiation (e.g. mammogram dose = approximately 0.4mSv) may increase breast cancer risk 
in these women; however there is little evidence currently to support this theory.  One 
paper examining this phenomenon found that there was an increased risk in these women 
when exposed to diagnostic radiation, especially at a young age.  When a comparison was 
made between no ionising radiation exposure and diagnostic radiation exposure in women 
under 30 years old the HR was 1.90 (95% CI; 1.20 – 3.00).  Again there was a correlation 
between higher doses of radiation and increased breast cancer risk, as previously 
established in non-BRCA mutation carriers(211): estimated dose <0.0020 Gy HR= 1.63, 
≥0.0020-0.0065 Gy HR = 1.78, ≥0.0066-0.0173 HR = 1.75, and ≥0.0174 HR = 3.84. 
Mantle field radiation is used in the treatment of Hodgkin Lymphoma; the breast cancer 
risk in women who have undergone this treatment is 75 times that of the general 
population(150).  There are several factors which modify this breast cancer risk such as 
time since treatment (latency approx. 15 years), age when treated, and dose(151).  
Exposure to this high dose radiation is proposed to cause loss or gain of function mutations 
and chromosomal rearrangements such as deletions and translocations, which act as an 
initiating step in the process of malignant transformation(151).  Another study carried out 
by Basu et al (2008) found in their cohort of 398 women diagnosed with paediatric 
Hodgkin’s Lymphoma that 25 women developed invasive breast carcinoma; and found that 
in their patient population there was a 37 fold increase in breast cancer risk(212).  
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Additionally they found that those women diagnosed with Hodgkin’s Lymphoma before the 
age of 12 had the highest risk of developing breast cancer, this was thought to relate to the 
developmental stage of the breast at this age(212).   
Exposure to high dose ionising radiation is a well-established breast cancer risk factor, 
which is an important consideration when assessing individual risk as recognised by both 
the UK NICE guidelines and the European EUSOMA guidance.   The exposure to low dose 
radiation, such as a mammogram, is not thought to increase the risk of breast cancer 
developing in later life.  However this is not thought to be case in women with familial 
breast cancer carrying BRCA1/2 mutations as they are less well equipped to cope with DNA 
damage.  However these investigations are ongoing and it is still not clear if BRCA1/2 
mutation carriers have an increased risk at lower doses of radiation.   
7. Ethnicity and Socioeconomic Status 
The highest breast cancer rates are associated with Caucasian women and women with a 
higher socioeconomic status (SES). Why this is the case is still unknown, but it is thought to 
be a complex combination of social, cultural and genetic factors. 
Studies from the USA show the highest breast cancer incidence is in white women and the 
lowest in American Indians/Alaskan Natives (see Table 2.2).  When compared to white 
women all other ethnic groups have a lower breast cancer risk, but only women of African-
American origin have a significant reduction in risk (HR = 0.85; 95% CI: 0.73-1.0)(119).   A 
study which was conducted on the UK population found that in comparison to the 
Caucasian population the South Asian population had a lower risk of developing breast 
cancer (HR = 0.81; 95% CI: 0.68-0.95)(152). 
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Ethnicity  Incidence of breast cancer per 100 000 
White 141 
African American 122 
Asian/Pacific Islanders 97 
Hispanic 90 
American Indians/Alaskan Natives 58 
Table 2.2:  Breast cancer incidence rates associated with different ethnic groups in the USA.  Results adapted 
from Chlebowski et al (2005)(119). 
SES and ethnicity can be linked; and one paper demonstrated that white women from the 
highest SES group had the highest breast cancer incidence, whereas African-American 
women from the lowest SES group had the lowest incidence of breast cancer(154).  Why 
this is the case is not well understood, however it may relate to social factors such as HRT 
use, age at FFTP or to the utilization of screening(154,213).  
Irrespective of how SES was calculated (educational status, income, community or 
individual area) women from a higher SES group always have the highest breast cancer 
incidence, and also  the best survival rates(153,155–157).  A 20% increase in breast cancer 
risk was demonstrated by Robert et al when they compared women living in areas with the 
highest SES with the lowest(157).  A different study found similar results (15% increase in 
risk) despite estimating SES using educational status(156).  The reasons for the difference in 
incidence between different SES categories may be explained by behavioural differences 
such as higher alcohol consumption, later age at FFTP, or lower parity which are all 
established risk factors in their own right - alternatively the disparity may be due to other, 
perhaps unknown, environmental and genetic factors.   
8. Mammographic Density 
Mammographic density is an established breast cancer risk factor which may have an 
association with the low penetrance polymorphisms discussed above, but it is not strictly 
an environmental factor.  However as it is an important contributor to risk it shall be 
discussed here.  Mammographic density describes the appearance of the breast on a 
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mammogram and refers to the composition of the breast tissue.  It describes the 
proportions of stromal and epithelial tissues which appear white on the mammogram; and 
fatty tissue which has a dark appearance(158,214).  Therefore a dense breast has a greater 
the proportion of epithelial and stromal tissue within it.   
High mammographic density was first hypothesised to be a risk factor in 1976 by Dr J 
Wolfe; who devised a  qualitative assessment method known as Wolfe grades (N, P1, P1 
and DY) for the assessment of breast density(161).  The issue with this grading system is its 
dependence on the reader and a great variability between readers has been noted.  Initially 
the increased risk associated with increased breast density was assumed to be due to 
masking bias, as dense tissue makes it more difficult to identify tumour.  However more 
recent work has reassessed the relationship between risk and density, and has found a 
strong association between increased density and higher breast cancer risk (215).  It is now 
generally accepted that a high mammographic density (>75%) imparts a 4 to 6 fold increase 
in breast cancer risk, when compared to women with a lower mammographic 
density(158,159,162,214). 
A meta-analysis which looked at 42 studies found that regardless of the method used to 
measure density (e.g. Wolfe grade or percentage density) there was an increased risk 
associated to higher breast densities (summarised in Table 2.3)(162).  It found that there 
was a relative risk of 4.64 (95% CI; 3.64 – 5.91) when women with >75% density were 
compared to those with <5% density(162). 
Density Vs <5% RR (95% CI) 
5-24% 1.79 (1.48-2.16) 
25-49% 2.11 (1.70 – 2.63) 
50-74% 2.92 (2.49 – 3.42) 
>75% 4.64 (3.64 – 5.91) 
Table 2.3 - Summary of the results published by McCormack and Silva, showing that with increasing 
mammographic density there is an increase in breast cancer risk.  Adapted from McCormack and Silva (162). 
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Other smaller studies are in agreement with the large meta-analysis.  For example Boyd et 
al found a RR of 5.86 (95% CI 2.2 – 15.6) when comparing >75% density to 0%.  This relative 
risk was adjusted for BMI, which allowed the authors to conclude that breast density and 
BMI are independent risk factors(159).  A study conducted within a Spanish population 
concluded that mammographic density was a risk factor for breast cancer in general, as the 
odds ratios were found to be similar for both DCIS (OR = 3.47; 95% CI 1.46 – 8.27) and 
invasive cancers (OR = 2.95; 95% CI 2.01 – 4.35)(216).  When looking specifically at receptor 
status Tamimi et al concluded that mammographic density was a risk factor for both ER and 
PR positive and negative tumours(163).  These results confirm that high mammographic 
density is a risk factor for breast cancers; however it does not predispose to any particular 
type or tumour characteristic.  
There are a lot of different hypotheses as to why breast density has an impact on breast 
cancer risk; these include higher circulating hormone levels, elevated growth factors, 
simply increased amounts of glandular parenchyma (therefore increasing the probability of 
developing a breast cancer) or unknown tumorigenic stromal factors (214).  Discovering 
which, if any, of these mechanisms are responsible for the relationship between risk and 
density is an active field of research.  Results emerging from this field include the nested 
case control study by Tamimi et al.  This study is part of the Nurses’ Health Study and 
explored the relationship between circulating hormone levels and density.  Both were 
found to be independent risk factors, as relative risk between the highest and lowest 
density quartiles did not significantly change when adjusted for hormone levels; RR = 3.8 
(95% CI: 2.2 – 6.6; p trend <0.001)(163).  These results are not suggestive that the increased 
risk associated with density is related to hormone levels, but it is too early a stage to rule 
out this mechanism. Pinto-Pereira et al (2011) demonstrated that cancers tend to develop 
in areas of focal and persistent mammographic density suggesting that the high epithelial 
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and stromal content of a dense breast is the underlying reason for increased breast cancer 
risk(217). 
One potential mechanism which may underlie the increased risk associated with high 
breast density is that there are unknown stromal factors acting in such a way that can lead 
to the development of breast cancer(214).  Therefore in an attempt to look at the stromal 
factors present in an established breast cancer the experiment in Appendix 5 was carried 
out.  The aim of this initial experiment was to extract RNA from formaldehyde fixed paraffin 
embedded tissue, which would allow analysis of gene expression and comparison between 
normal, reactive and tumour stromal tissue.  However due to the fixing process the quality 
of the RNA was too low to allow any further analysis as certain quality control standards 
must be met to allow real-time polymerase chain reaction (RT-PCR) or microarray analysis.   
Nonetheless the concept of further investigating the gene expression within  the stromal 
tissues surrounding cancers would be of interest to pursue further in the future; as this has 
the potential to link into both the genetic risk factors, which may have altered expression, 
and may also differ depending on distance from the tumour.  To do this in the future would 
likely require RNA extraction from fresh frozen tissue, which brings with it a number of 
logistical issues; however a protocol for collecting tissue in this way was also written and 
can be found in Appendix 5.  Unfortunately due to time constraints and the problems with 
identifying suitable candidates further molecular genetic analysis was not possible at this 
time.  In the future analysis of the gene expression, particularly the low penetrance genes 
identified to effect breast cancer risk, would provide an interesting focus of research and 
perhaps allow the examination of the mechanisms by which breast cancer develops in 
further depth. 
Irrespective of the underlying biological mechanism the evidence clearly points to 
mammographic density having a strong association with breast cancer risk.  It is now widely 
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accepted that having high density breasts causes a 4 to 6 fold increase in risk, which is an 
effect of the high density itself and not due to masking bias.  Some estimates predict that 
high breast density could account for up to 30% of all breast cancer cases(161). 
9. Gene-Environment Interactions 
During the previous chapter the effect of gene-environment interactions on risk were 
touched upon; for example ZNF365, LSP1 and RAD51L1 have all been associated with 
mammographic density(74,81).  This demonstrates a relationship between genetic and 
environmental risk factors which act together to alter risk.  It is also becoming clear that 
common processes or pathways are involved as the proposed mechanisms by which 
multiple genetic and environmental risk factors confer risk.  For example oestrogen 
signalling and DNA repair pathways have been implicated in the plausible mechanisms for 
various factors discussed in this literature review.  Therefore breast cancer research has 
begun to investigate interactions between genes and environment, in the hope that the 
poorly understood underlying biological mechanisms which are involved can be elucidated.  
This is in turn is hoped to have preventative and risk prediction benefits(218).    
Far fewer studies have been published on the subject of gene-environment interactions as 
this is a newly developing field in breast cancer research.  However the focus of the 
published articles on this subject have been on reproductive risk  factors; particularly age at 
menarche, age at natural menopause, parity and HRT use(8,219–222).  As of yet there is 
not a conclusive body of evidence demonstrating a positive correlation between any of the 
genetic and environmental risk factors, with many authors producing null 
results(8,220,221,223).   
There have however been some positive findings, but in many cases these results have not 
yet been replicated.  One such study by Nickels et al(219) found associations between 
several SNPs and environmental factors in their large collaborative study with 34,793 cases 
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and 41,099 controls. In this study they found that there were associations between LSP1 
and parity, NOTCH2 and parity, and CASP8 and alcohol. There was also weak evidence that 
the risk conferred by RAD51L1 was modified by HRT use(219).  On the other hand a 
previous paper published as part of the MWS failed to find any significant associations 
between FGFR2, TNRC9, MAP3K1, CASP8, LSP1 and ATM and a range of environmental risk 
factors(220).  However, these authors did find a relationship between higher alcohol 
consumption and CASP8; finding that there was an increase in breast cancer risk per allele 
in women who had one or more drinks a day in when compared to women who had less 
than one alcoholic drink a day.  In addition to relationships between TNRC9 and age at 
menarche, age at menopause and HRT which were all of borderline significance(220). 
Other authors have found differing associations, for example CASP8  has also been 
associated with a decrease in menopausal age by 1.12 years for each A allele a participant 
had in a small cohort(222).  However in a second verification cohort these results could not 
be replicated, and there was no information provided on the effect on breast cancer risk.  
Nonetheless it could be inferred that this would increase risk, as an older age at 
menopause has been found to increase an individual’s relative risk of breast cancer(111).   
An earlier paper by the same group did however look at how these interactions could 
modify breast cancer risk, and found that women with a larger gap between menarche and 
FFTP had an increased risk of breast cancer if they were heterozygous or homozygous for 
the G allele of 5p12 (PDCD9)(224). 
There seems to have been a particular interest in the study of FGFR2 and its interactions 
with environmental risk factors; this may be because it has been consistently replicated 
and seems to confer the largest relative risk of all the low penetrance polymorphisms 
identified.  There is some evidence to support that FGFR2 may increase risk of HRT therapy, 
and in particular oestrogen only therapy(225).  However other studies have been unable to 
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replicated this finding(220,226).  The risk associated with FGFR2 has also been found to be 
modified by age at menarche, parity and a BMI>25 in post-menopausal women(226).  The 
interactions identified between FGFR2 polymorphisms, reproductive factors and ER 
positive tumours has led to hypotheses that these polymorphisms may influence breast 
cancer risk via hormonal pathways(225).   
It has been proposed that some genes act to modify breast cancer risk only in combination 
with environmental factors; these genes will therefore be missed by GWAS and other such 
genetic studies.  One group is therefore utilising gene-environment interactions to identify 
novel genetic risk factors(227).  In this way two SNPs on Runt related transcription factor 1 
(RUNX1) were identified in association with BMI to decrease risk with increasing BMI.  
However for these results to be replicated it would require huge numbers and a great deal 
of epidemiological and genetic information. 
Finally, very little attention has been paid to the higher penetrance risk genetic mutations 
associated with breast cancer as these may also interact with their environment.  Dennis et 
al looked at alcohol consumption and BRCA mutations to see if high alcohol consumption 
influenced breast cancer risk.  Unfortunately this paper had very few BRCA1 (n = 10) and 
BRCA2 (n = 33) mutation carriers, but their findings did suggest an increase in breast cancer 
risk in BRCA2 carriers who consumed more alcohol(228).  However further studies with 
larger numbers of BRCA mutation carriers would prove interesting, and help to identify if 
environmental factors modify the risk associated with these high penetrance mutations. 
By looking at gene-environment interactions a great deal of information on biological 
mechanisms may be gained and there is also the opportunity to identify novel genetic risk 
factors.  However as this is a developing field there is still limited evidence available and 
apparent issues with reproducibility(229).  In addition the current evidence concentrates 
heavily on reproductive factors with fewer studies investigating other risk factors such as 
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BMI, alcohol, smoking and radiation exposure.  The patient populations which have been 
studied to date also have a heavy emphasis on Caucasian populations, but there is already 
evidence that ethnicity influences breast cancer risk(119) therefore it is feasible the gene-
environment interactions would differ in these populations.  Finally the majority of the 
research is looking for interactions between any gene and any environmental factor, 
without taking into account what is already known about the proposed biological 
mechanisms thought to underlie risk in each case.  For example by hypothesising that the 
ESR1 gene may interact with the reproductive risk factors, alcohol and BMI to alter risk - as 
all are thought contribute to risk via hormonal mechanisms - would perhaps be more likely 
to produce reproducible associations between genes and environment.   It is clear that by 
using the current knowledge on individual breast cancer risk and prognostic factors, and 
applying it in a more holistic way to look at the patient as combination of their genes and 
environment, there is an opportunity to look at breast cancer risk in a new way.  This 
different perspective on breast cancer risk and prognosis may provide insight into 
underlying biological mechanisms and there contribution to risk, as well as identifying new 
genetic risk factors.   
10. Conclusion 
There are a huge number of articles which have been published that investigate the various 
different environmental factors that have been proposed to contribute to breast cancer 
risk.  Evidence for some risk factors, such as the use of hormonal preparations, is extremely 
consistent and has led to them becoming generally accepted as contributing to breast 
cancer risk.    On the other hand evidence for other risk factors is far from consistent and 
no consensus can be reached as to whether these things influence risk at all, an example of 
such a factor would be diet.  However, the reason for this lack of evidence may be due to 
the difficulties faced by researchers when trying to design studies to evaluate these  
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Table 2.4 – Summary of the relative risks attributable to each of the environmental factors which this thesis 
has found to have good evidence of association with breast cancer. 
environmental factors.  In addition to the effort involved in running these studies and 
numbers of patients required to be recruited for this type of study to reach significance. 
This brief literature review demonstrates that there are a number of environmental factors 
which contribute to risk some of which are potentially modifiable and could be used 
preventatively: for example obesity, smoking, alcohol intake and breast feeding.  The best 
established risk factors include breast density, age at menarche, menopause and FFTP; 
Risk Factor RR Reference 
Age at Menarche: Every year <13 
years at menarche 
1.05 Collaborative Group on Hormonal 
Factors (2012)(173) 
Age at Menopause: every year older 
at menopause 
1.029 Collaborative Group on Hormonal 
Factors (2012)(173) 
Age at FFTP: ≤19years Vs ≥35years 
at FFTP 
2.0 Li et al (2007)(174) 
Parity: Parous Vs Nulliparous 0.91 Ma et al (2010)(113) 
Breastfeeding: Ever Vs Never 0.75 Stuebe et al (2009)(112) 
HRT: Current Vs Non-user 1.22-1.43 Collaborative Group on Hormonal 
Factors (1997)(110); Millions Women 
Study Collaborators (2003)(117) 
HBC: OCP Current Vs Non-users 1.24 Collaborative Group on Hormonal 
Factors (1996)(118) 
BMI: Postmenopausal women 
highest Vs lowest quartile BMI 
1.54-1.57 Lahmann et al (2003)(185); Han et al 
(2006)(126) 
BMI: Premenopausal women 
highest Vs lowest group 
0.58 Brandt et al (2000)(127) 
Diabetes Mellitus: Type 2 DM Vs No 
diabetes 
1.20 Larsson et al (2007)(188) 
Alcohol Consumption: >4-5.5 units 
of alcohol daily Vs no alcohol 
1.32 Hamajima et al (2002)(139) 
Active Smoking: Active smoking Vs 
non-smoker 
1.32 Reynolds et al (2004)(196) 
Ionising Radiation: Therapeutic 
radiation Vs no medical radiation 
exposure 
1.72  John et al (2007)(210) 
SES: Highest Vs Lowest SES groups 1.15-1.20 Webster et al (2008)(156); Robert et al 
(2004)(157) 
Mammographic Density: >75% 
density Vs <5% density 
4.64 McCormack and Silva (2006)(162) 
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parity; obesity (BMI); use of hormonal preparations; history of active smoking; ionising 
radiation; alcohol consumption and SES (Summarised Table 2.4).   
There is less evidence which support a role for diet, environmental exposures and passive 
smoke exposure in breast cancer.  However none of these factors have been ruled out as 
playing a potential role in risk and research is ongoing.   
The factors which have been discussed in this chapter are all potential risk factors, however 
alone none of these risk factors are solely causative – perhaps with the exception of 
ionising radiation exposure.  These risk factors contribute a small to moderate relative risk, 
which when combined with other environmental and genetic risk factors cause a woman to 
reach a threshold of risk and develop breast cancer.  Additionally it is believed that there 
are also interactions between the genetic factors outlined in the previous chapter and the 
epidemiological risk factors reviewed above.  However this is a relatively new area of 
research in the breast cancer field so there is a limited number of high quality research 
papers published on this subject.  It is clear that there is now evidence emerging that these 
gene-environment interactions have the potential to modify breast cancer risk.  One reason 
for this may be that both the genetic loci and epidemiological risk factors are converging in 
similar pathways to cause this increase in risk.  Therefore by improving our understanding 
of these interactions we can uncover the biological mechanisms involved in breast cancer 
which are currently fairly poorly understood.   
It is therefore clear that for the majority of breast cancers, with the exception of some 
familial cancers, there is a complex interplay between genetics and environment that result 
in its development.  So by improving our understanding of not only these risk factors as 
single entities but as a whole and as part of complex biological machinery then we can 
understand an extremely common yet complex and heterogeneous disease better. 
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Environmental Factors which Alter 
Risk of Recurrence and Prognosis  
1. Introduction 
Breast cancer is a highly prevalent disease with over a million new cases reported 
worldwide each year(3).  However the screening and treatment of breast cancer is 
improving and in the US alone there are 2.3 million breast cancer survivors(230).  Patterson 
et al estimates that women diagnosed with breast cancer in 2009/10 will have a 5 year 
survival of 89% and 10 year survival of 82%(231). These predictions by Patterson et al are 
also in line with the findings of the survival analysis, which is outlined in the next chapter.  
This has led to an increase in the quantity of research into factors which influence disease 
prognosis.  There is a special interest in modifiable environmental prognostic factors, which 
can be used to reduce the rates of recurrent disease and reduce breast cancer specific 
mortality.   
It is hoped that if strong evidence is found in support of lifestyle modifications and better 
disease outcome, that patients can be given advice about lifestyle and make changes 
accordingly – however it must be noted that patients do not always adhere to this 
advice(232).  Therefore studies in this area are popular, aiming to define the advice 
patients should be given to reduce recurrence rates, which is a new clinical challenge due 
to increasing survival(231).   
The evidence for various environmental influences on breast cancer prognosis shall be 
reviewed to highlight the key modifiable influences on breast cancer outcome.  When 
reading and comparing these papers it is important to note that there is considerable 
variation in the definition of outcome and also in the time points at which the data is 
collected.  This means that there can be difficulties in making direct comparisons between 
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papers.  For the purpose of this chapter the prognostic outcomes focussed on shall be 
disease free survival or recurrence, breast cancer specific mortality and all-cause mortality.  
These are also the outcome measures used in the analysis of survival in a Tayside cohort 
described in the next chapter.  Special focus shall be given to diet, exercise, body weight 
and hormonal factors, as these are the factors with the biggest body of evidence and that 
have previously been discussed with regards to environmental risk.  As there is a possibility 
that some prognostic factors may be linked to environmental and genetic risk factors 
through common biological processes. 
As with the literature review of reproductive and environmental risk factors this literature 
review is journalistic in nature.  Medline searches where conducted using “breast 
neoplasms” AND “prognosis”, with an appropriate accompanying MeSH search term (see 
Appendix 3).  Suitable articles were identified using the abstracts with an emphasis on 
using the larger cohort, case control studies, systematic reviews and meta-analyses.  Once 
again further articles were identified using the references of articles which were identified 
by the Medline search.  
2. Dietary Influence on Prognosis 
Diet is of special interest as it potentially plays a role in breast cancer risk, as outlined in the 
previous chapter.  It can also be easily altered to fit recommendations in individuals who 
are motivated enough.    However these studies must always be interpreted with some 
caution as assessing and quantifying a diet poses considerable challenges.  There is also 
some discrepancy as to when the information on diet is collected – pre-diagnosis, at 
diagnosis or post diagnosis(230,232).  Diet is also expected to change throughout this 
period and that using self-reported food frequency questionnaires (FFQ) may not provide 
accurate data.  Even in cohort studies which look at participants prior to diagnosis do not 
take into account prior diet and have the difficulty of how often to assess diet. 
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The challenges of this type of study are reflected in the inconsistency of the evidence as to 
whether diet has any influence on prognostic end points, which are usually defined as 
breast cancer specific mortality, recurrence or disease free survival.  Some specific food 
groups have been studied in particular due to their mechanistic plausibility and their 
relationship with risk - particularly fruit, vegetables, fibre and fat content.   
The HEAL (healthy eating, activity and lifestyle) cohort consisted of 688 women with a 
median of 6.7years follow up.  In this study they used a FFQ to assess fibre intake and 
carbohydrate intake which were compared with breast cancer specific mortality and 
recurrence.  They found a non-significant inverse relationship between high fibre intake 
and mortality(233).  The hazard ratios (HR) reported between the high and low fibre intake 
were 0.53 (95% CI 0.23 – 1.23) and 0.75 (95% CI 0.27-1.70).  A similar non-significant trend 
was seen with recurrence (HR = 0.68 (95% CI 0.27 – 1.70)(233).   
Fibre is thought to potentially have a protective effect through its ability to decrease 
oestrogen levels(233) and the levels of inflammatory markers such as C reactive proteins 
(CRP)(234).  Raised levels of these markers have been associated with poor outcomes(235).   
The results from McEligot et al associated diets high in fibre, fruit and vegetables with a 
better outcome in a group of women with breast cancer.  In this study diet was assessed by 
a FFQ for the year prior to diagnosis, which was completed by subjects(236).  The patients 
with the highest versus lowest fibre intake had a HR = 0.48 (95% CI 0.27-0.86; p trend = 
0.01).  This study also investigated fat, fruit and vegetable consumption.  High fruit and 
vegetable intake was associated with small protective effect against all-cause mortality in 
women diagnosed with breast cancer; highest versus lowest intake of vegetables HR = 0.57 
(95% CI 0.38-0.94; p trend = 0.02) and fruit HR = 0.63 (95% CI 0.38-1.05; p trend = 0.08).  
Pierce et al in the WHEL study showed a similar but insignificant trend for improved 
outcome with high fruit and vegetable consumption(237).   
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The WHEL study followed a cohort of 3088 women with breast cancer, 1537 of these 
women were placed in an intervention group.  These women were given extensive dietary 
advice and cooking classes with the aim of exceeding their “5 a day”.  The two groups were 
then compared in terms of diet and outcomes.  The intervention group ate significantly 
more fruit and vegetables over the 7.3 years follow up (p<0.001).  However there was no 
difference between recurrence (HR = 0.96; 95% CI 0.08-1.14, p = 0.63) or overall survival 
(HR = 0.91; 95% CI 0.72 – 1.15, p = 0.43)(237).  
A similar interventional study was carried out looking at dietary fat reduction and breast 
cancer free survival in women diagnosed with early stage breast cancer.  The women’s 
intervention nutrition study (WINS) recruited 2437 women aged between 48 – 79 years up 
to one year after diagnosis(238,239).  These women were then divided into the 
intervention and control groups; the intervention group then received intensive counselling 
from a dietician with the aim of reducing dietary fat to 15% of total energy intake.  After an 
average of 60 months of follow up it was found that there was marginal increase in disease 
free survival in the intervention group – HR = 0.76 (95% CI 0.60 – 0.98; p = 0.077)(12).  The 
evidence for dietary intervention is not consistent; however there is evidence that a 
healthy diet with low levels of fat, high fibre, fruit and vegetables is generally good for our 
health and wellbeing.   
It is a similar picture for alcohol consumption, which is an established risk factor for 
developing breast cancer, as demonstrated in the previous chapter.  A number of studies 
on the topic of outcome and alcohol have produced non-significant results; however some 
do perhaps suggest a trend for increased mortality with higher alcohol consumption.  Holm 
et al conducted a cohort study in a large group of Danish women with the aim of assessing 
pre-diagnostic alcohol consumption and breast cancer prognosis.  Women who drank the 
most (>2units a day), when compared to those who drank the least (<1 unit daily), had 
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small significant increase in risk of breast cancer recurrence - HR = 1.65 (95% CI 1.02 – 2.67; 
p = 0.04)(240). 
In contrast a study of 3088 women that assessed alcohol intake via the Arizona FFQ and 24 
hour recall phone calls, concluded that there was no significant association between light 
alcohol intake (10-290g alcohol per month) and breast cancer recurrence – HR = 0.91 (95% 
CI 0.71 – 1.18).  They also concluded that the highest alcohol consumption (>300g per 
month) was protective against all-cause mortality when compared to the lowest 
consumption group – HR = 0.70 (95% CI 0.48 - 1.02)(241).  These results are in agreement 
with Reding et al who also found that alcohol consumption, regardless of quantity, was 
associated with increased survival: HR = 0.7 (95% CI 0.5 – 0.9)(242).   
Patterson et al reviewed all the relevant papers on the subject that had been published up 
to 2010.  The results of some of these are summarised in Figure 3.1, illustrating the HR for 
all-cause mortality and alcohol consumption in women diagnosed with breast cancer.  They 
concluded that there was a lack of consistency in the work on breast cancer outcome and 
alcohol consumption which warranted more work(231).  However, as for diet, there are 
difficulties with assessing alcohol intake and variable intake over a lifetime; therefore more 
work is needed to develop conclusive evidence(232,240).   
 
Figure 3.1 – A Forrest plot which demonstrates that there is little consensus as to whether alcohol 
consumption is associated with mortality in women diagnosed with breast cancer. Adapted from Patterson et 
al(231) 
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3. Body Weight and BMI 
Having a high body mass index (BMI) has been shown to be a risk factor for the 
development of breast cancer in postmenopausal but not premenopausal women, as 
outlined in second chapter of this thesis.  It has therefore been hypothesised that by similar 
mechanisms being overweight may be associated with poorer outcomes in patients 
diagnosed with breast cancer; namely the increased circulating free oestrogens due to the 
conversion ability of adipose tissue or the association with increased insulin, insulin 
resistance and circulating insulin-like growth factor(243–245).  It is also important to note 
that women who are overweight often present with larger and/or higher grade tumours at 
diagnosis, which are both established poor prognostic indicators(246). 
The majority of the evidence suggests that a high BMI or obesity are negative prognostic 
indicators(244,246–251).  However a small number of studies have found no association, 
for example Carmichael et al failed to find any association in their cohort of 1579 
women(249).  This study is however smaller in size than the majority of the other studies 
included in this review, and therefore may not have the statistical power to find a very 
small but significant association between the two. 
A review by Chlebowski and McTiernan in 2002 stated that there had been 34 studies to 
date on the topic which met their inclusion criteria, and of these 26 produced statistically 
significant results in favour of a relationship between obesity and poor outcome(252).  This 
is supported by a meta-analysis of 12 papers in 2001 (Figure 3.2), which gave an overall HR 
of 1.56 (95% CI; 1.22-2.0) of highest versus lowest measures of weight(251).  
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Figure 3.2 - Effect sizes, overall effect size and 95% confidence intervals for BMI and prognosis (all cause 
death) from the meta-analysis by Ryu et al summarising the findings.  Adapted from Ryu et al (251). 
More recent data also supports this meta-analysis.  For example a study of 5042 breast 
cancer patients over a, relatively short, average follow up of 3.8 years found HR = 1.44 
(95% CI; 1.02-2.03) when comparing women with a BMI >30 to those with a BMI 18.5-
24.9(248). However when comparing women who were overweight (BMI 25.0 – 29.9) to 
those with a normal BMI (18.5 – 24.9) HR = 1.06 (95% CI 0.86 – 1.31) no significant 
difference was seen.  Both these hazard ratios relate to the recurrence/disease specific 
mortality outcome of this study, as obesity is associated with a number of comorbidities 
which could potentially increase all-cause mortality rates in women with the highest 
BMI’s(248).     
Ewertz et al also found that obesity was an independent prognostic factor, associated with 
poorer outcomes in women with breast cancer(246).  Women with BMI’s over 30 were 
24.3% more likely to be found to have distant metastases.  This same group of women 
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were also 57.2% more likely to die after their breast cancer diagnosis over an 11.4 year 
follow up.  The authors of this paper questioned whether perhaps the poor prognosis of 
these women was linked to a decreased effectiveness of adjuvant treatments in women 
who are overweight(246).  This theory though logical still requires the backing of evidence.   
The majority of the above studies are in populations of predominately postmenopausal 
women, and relatively few focus on premenopausal women despite menopausal status 
influencing if BMI is a risk factor for breast cancer. One paper by Enger et al observed a 
non-significant trend towards decreased risk of breast cancer death in the women with the 
highest versus lowest BMI in a group of premenopausal women (253).  Finding a 25% 
reduction in breast cancer death among the women with the highest BMI compared to a 
normal BMI (p trend = 0.21).  However this was a fairly small cohort of 717 women and the 
result was insignificant, so this being a result of chance cannot be ruled out.   
A second paper by Loi et al had a study population that consisted of 74% premenopausal 
women.  In the group of premenopausal women the HR for disease recurrence was 1.50 
(95% CI 1.00 -2.26; p =0.06) in obese (BMI >30) in comparison to non-obese women(254).  
It is not as clear as to whether obesity effects the prognosis in premenopausal women – of 
the 10 papers referenced by Loi et al only four produced a statistically significant 
association between the two(254).  More work is needed in this are to define the 
relationship between menopausal status and weight in terms of outcome. 
Another area of interest is weight change after diagnosis and its effect on survival or 
recurrence of breast cancer. This is of special interest as it is very common for women 
undergoing breast cancer treatment to gain weight (252,255,256).  Potential reasons for 
this weight gain are increased intake, decreased activity or reduced metabolism – the 
actual mechanism underlying this observed weight gain remains unknown(252). 
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Caan et al found no association between weight gain and recurrence over an average of 6.1 
years follow up(256).  In this case recurrence was defined as all local and distant 
recurrences or development of a contralateral breast cancer.  The hazard ratios were 0.8 
(95% CI; 0.6 – 1.1) and 1.0 (95% CI; 0.7 - 1.3) in women who gained 5-10% and >10% of 
their body weight respectively(256).   
A study carried out on 5204 women from the Nurses Health Study (NHS) observed a 
decrease in survival in those who gained weight post diagnosis, a relationship which 
seemed to be more significant in never smokers (Table 3.1)(244).  In this study weight gain 
was associated with both increased risk of recurrence and mortality.  
Breast Cancer 
Deaths 
Category BMI Change (kg/m
2
)  
 > 0.5 Loss Maintained 0.5 to < 2.0 
Gain 
> 2.0 Gain  
Never smokers: 
RR (95% CI)   1.01 
(0.65 – 1.58) 
1.00 1.35 
(0.93 – 1.95) 
1.53 
(1.04 – 2.24) 
 
P trend = 0.03 
Past & Current Smokers: 
RR (95% CI) 1.18 
(0.85 – 1.63) 
1.00 1.10 
(0.83 – 1.47) 
1.05 
(0.78 – 1.43) 
 
P trend = 0.84 
Table 3.1 - Summary of the breast cancer specific mortality from NHS stratified by smoking status.  Adapted 
from Kroenke et al(244). 
The evidence generally supports the association between BMI and poor outcome in 
postmenopausal women, but it is less clear if the same relationship exists in 
premenopausal women.  This is in part due to fewer studies having been carried out in 
populations of premenopausal women.  There are indications that weight gain after 
diagnosis has a negative influence on prognosis.  However further studies in this area will 
need to be carried out to come to a clear consensus as to the importance of weight 
maintenance after breast cancer diagnosis.   It is also unclear as to whether encouraging 
weight loss in overweight women will improve their outcome.  There is a need for more 
intervention studies to bring clarity as to whether weight loss would be beneficial(257).   
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There is less published work that tackles the issue of underweight women (BMI <18.5 
kg/m2) and breast cancer prognosis.  However it is thought that the relationship between 
weight and breast cancer survival may be U or J shaped; therefore there is a need to 
address the survival of women with low BMIs at diagnosis(illustrated in Figure 3.3)(258).  A 
large pooling project with almost 15000 participants found that after 7.8 years follow up 
underweight women (BMI <18.5 kg/m2) had higher overall mortality – HR = 1.59 (95% CI: 
1.18 – 2.13).  However they did not find an association with recurrence or breast cancer 
specific mortality and a low BMI at diagnosis(258).  On the other hand a large Korean study 
found an association between underweight patients and breast cancer specific mortality 
(HR = 1.49; 95% CI: 1.15-1.93)(259).  There clearly needs to be more work done to elucidate 
the relationship between breast cancer prognosis and low BMI as there are strong 
indications that it is also a negative prognostic marker. 
The evidence suggests that obesity and perhaps low body weight has an impact on the 
outcome of the disease, indicating that both high and low BMI’s at diagnosis may have a 
negative impact on outcome.  Additionally weight change during treatment may also have 
Increasing Postmenopausal BMI 
at Diagnosis 
Increasing 
Relative Risk of 
Breast Cancer 
Figure 3.3 - This illustrates the J or U shaped relationship which is thought to exist between breast 
cancer outcome and BMI in postmenopausal women. 
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some influence over a patient’s prognosis.  However the mechanism underlying these 
relationships is unknown and if this relates to circulating oestrogen levels is still an area of 
active research. 
4. Physical Activity 
Physical activity is associated with decreased breast cancer risk, but the relationship 
between physical activity and breast cancer prognosis needs further elucidation(260).  The 
difficulty in assessing physical activity is selecting the time point at which to assess activity; 
for example is it best to assess exercise pre-diagnosis, post diagnosis, at another specific 
time point or estimate lifetime exercise.  A clear decision as to which one of these is the 
best or most relevant time period has not been agreed upon, making it more difficult to 
directly compare the evidence from the various published papers. 
A recent systematic review of the role of physical activity on cancer prognosis in general 
found that the majority of the evidence supported a relationship between increased 
exercise and increased breast cancer survival(261).  It summarised that of the 17 relevant 
observational studies identified in their database search 4 papers produced null results, 7 
found a non-significant associations and the remaining 6 identified a significant association 
between increased physical activity and increased survival.  However publication bias 
cannot be ruled out and these published papers with null results may represent the tip of 
the iceberg.  There is no way of knowing if this bias is affecting this or any of the factors 
discussed in this chapter. 
A study which specifically examined the impact of pre-diagnostic physical activity on breast 
cancer outcomes, found that women who had partaken in moderate lifetime exercise were 
less likely to die from breast cancer than those who had done no exercise (HR=0.64; 95% 
CI=0.43-0.93)(262).  It also found that this relationship was strengthened in those who had 
done exercise during menopause.  The caveat with this paper is that it required self-
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reported estimates of exercise at various points in life, which have the potential to be 
inaccurate.   
Other papers have assessed exercise following diagnosis at various time points, for 
example 6, 18 and 36 months after diagnosis.  Chen et al found that at 36 months regular 
exercisers versus non exercisers had a lower risk of recurrence and disease specific 
mortality; HR = 0.6 (95% CI; 0.47 – 0.76)(263).  However the authors highlighted that low 
levels of exercise may be due to poor health, which in turn is responsible for the increased 
survival in those who are doing more exercise.   
Potential mechanisms that may underlie the observed increase in survival and decreased 
recurrence rates with increased physical activity include: decreased oestrogen levels, 
increased immune functions, lower body fat or decreased insulin resistance(260,262).  The 
relationship between physical activity and breast cancer prognosis is hard to interpret.  
More work may be required to identify when in particular exercise is important in terms of 
survival – lifelong, after menopause or after diagnosis?  Additionally as highlighted by Chen 
et al post-diagnosis exercise is in part dependent on the patients’ health and response to 
treatment, therefore the patients partaking in the highest levels of exercise are in better 
health than those who do not.   
5 Hormone Replacement Therapy and Survival 
Hormone replacement therapy (HRT) is generally well accepted as a risk factor for 
developing breast cancer due mainly to three large studies which were published in the 
1990’s (117,118,178). These papers have been discussed in depth during the course of the 
previous chapter.  However the effect of HRT on breast cancer prognosis has been a recent 
area of interest.  It has been noted by numerous papers that there seems to be increased 
survival in women using HRT at the time of diagnosis.  The reasons for these observations 
are still under debate – it may be due in part to the increased mammographic surveillance 
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these women are under as they have a higher breast cancer risk.  There is also some 
evidence that HRT is associated with tumours that have better prognostic factors(264–
268).  For example current long term use of HRT was associated with the diagnosis of a 
grade 1 opposed to a grade 3 tumour when compared to women who never used HRT (OR 
= 0.3; 95% CI 0.2 – 0.5)(264).  This may again be due to mammographic surveillance or 
greater awareness of breast cancer and therefore self-examination in this population of 
women. 
A paper published in 2008 which followed a group of 2660 breast cancer patients for 
approximately 9.3 years, found that women who were using HRT at diagnosis were at a 
lower risk of dying due to the breast cancer (HR = 0.57; 95% CI 0.41 – 0.79).  However, this 
paper found no association between survival and past use(264).  This is in agreement with 
Barnett et al who found a decreased risk of death in women who used HRT for >4years 
than non-users (HR = 0.65; 95% CI, 0.51 to 0.84; P= 0.001).  The authors also found no 
association between prognosis and age at menopause/menarche, smoking history or 
previous use of the oral contraceptive pill (OCP)(266). 
Other authors have also specifically found that women who use HRT have tumours that are 
more likely to be smaller, lower grade and node negative; which are some of the most 
important prognostic indicators in breast cancer care(267).  Fletcher et al expanded on this 
idea by adjusting for these characteristics in their statistical analysis.  Prior to adjusting for 
tumour characteristics HRT use was associated with increased survival (HR = 0.64; 95% CI 
0.41 – 1.00).  This modest increased in survival was lost after adjusting for the tumour 
characteristics, suggesting that these tumour characteristics may in part be responsible for 
the survival benefit of taking HRT(268).   
The explanation of the better prognosis associated with HRT use is still poorly understood, 
however there have been several suggestions made as to why this is the case.  These 
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include the tumour characteristics, socioeconomic status, educational level of women 
taking HRT, screening, or that these women may be more likely to be health 
conscious(268).  Additionally HRT is thought to increase risk as it increases the amount of 
available exogenous hormones, when a patient it diagnosed with breast cancer this 
exogenous source of hormone will be removed which may also influence prognosis.   
The relationship between the OCP and breast cancer prognosis is less clear, with the 
majority of the evidence finding no association(266,269–271).  This lack of association is 
consistent regardless of duration(271), latency or recency of use(270).  The body of the 
evidence suggests that there is no association between OCP use and breast cancer 
prognosis.  However there is more evidence needed to define the relationship between 
HRT or HBC use and breast cancer survival; as current indications suggest current HRT use 
has a survival benefit, but HBC use does not.   
6. Socioeconomic Status 
A high socioeconomic status (SES) has been established as a risk factor for developing 
breast cancer(272), however like many other cancers a lower SES has been linked to poor 
prognosis(256,272–278).  Various reasons for this link have been hypothesised ranging 
from access to health care, treatment options and tumour biology(272,273,279).  
Making direct comparisons between papers can be difficult due to the various different 
measures of SES – for example one paper used the occupation as a measure of 
deprivation(272), whereas other papers have used the Carstairs deprivation index 
score(276).  However it must be noted that regardless of what measure of SES used the 
results remain generally constant with lower SES being associated with a worse prognosis 
than the highest SES. 
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A Swiss study on a group of 3920 women diagnosed with breast cancer before the age of 
70 used occupation to determine SES.  This meant that housewives were classified as being 
of a low SES regardless of their home situation, which may prove to be inaccurate.  Perhaps 
an estimated household income or the area in which they lived would have been a more 
accurate way of estimating SES in this study.  However the results of this study are in 
agreement with the bulk of the literature finding that women of the lowest SES were at the 
highest risk of dying from breast cancer – HR = 2.4 (95% CI 1.6 – 3.5)(272).  This hazard ratio 
only partially decreased (HR = 1.8; 95% CI 1.2 – 2.6) when the results were adjusted for 
tumour characteristics, delayed diagnosis and treatment options - leading the authors to 
conclude that SES is an independent prognostic factor(272). 
There have also been papers published that specifically focus on the Scottish population, 
which is particularly relevant to survival analysis which has been carried out on a Tayside 
cohort in the following chapter.  Thomson et al found in their data set of 21,751 women 
diagnosed with breast cancer before the age of 85, that there was an 8.7% survival 
difference between the highest and lowest deprivation categories(275).  A second paper 
which looked at women diagnosed with breast cancer from 1986 to 2000 in the Scotland 
used the Carstairs deprivation index score to categorise SES.  It found that in women 
diagnosed with breast cancer between 1996  to 2000 there was a 4.1% difference in 5 year 
survival between women in the highest and lowest SES groups(276). 
A large study conducted in the Netherlands also agreed with the above results.  Finding a 
significantly lower 10 year overall survival in women in the very low SES group in 
comparison to the very high SES group (HR = 1.10; 95% CI 1.06 – 1.13; p <0.001)(277).  The 
results of this paper are summarised in Figure 3.4.  
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Figure 3.4 - A graphic representation of the relative survival of women diagnosed with breast cancer 
according to their assigned SES.  Adapted from Bastiaannet et al (277). 
It is clear from the evidence that SES does have an association with patient prognosis.  
However what this is due to is still unclear – there is evidence that in part it is related to 
tumour biology for example one paper examined the presence of p53 mutations in 
deprived patients(273), and other tumour size(277).  It could also be related to assess to 
health care and to the treatment options available to patients, further work will need to be 
carried out to elucidate the mechanism behind this association(279).  This subject is 
covered in more depth in a further chapter with regards to the survival analysis carried out 
on a Tayside cohort, which plays particular attention to the effect that deprivation has on 
breast cancer survival.  
7. Conclusion 
There is a great deal less epidemiological work on the association between various 
modifiable lifestyle factors and breast cancer prognosis in comparison to the work done on 
breast cancer risk.  The value in this work lies in the advice that can be offered to patients 
after diagnosis, which could allow them to make lifestyle changes to improve their 
outcome(232). 
The greatest evidence is in support of an association between improved prognosis and a 
normal BMI at diagnosis and, weight loss after diagnosis.  The literature also indicates that 
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the use of HRT at the time of diagnosis and a higher SES may be prognostically favourable.  
However the evidence is less clear for the role of diet, exercise or the use of the OCP.  One 
reason for this may be the difficulties in studying these factors due to the difficulties in 
setting parameters, relying on short follow up and self-reporting.   
However, some of these factors may influence both prognosis and risk but in different 
ways.  An example of this is SES as a high SES increases the risk of breast cancer but is 
associated with a better outcome than a lower SES.  The reason for this difference is once 
again not known, but it may relate to gene-environment interactions or may relate more to 
behavioural reasons.  The study of gene-environment interactions and breast cancer 
prognosis is in the extremely early stages.  Preliminary data suggests that it is likely to be 
different low penetrance polymorphisms which influence prognosis and risk(280).  To date 
there is no reliable evidence that any of the SNPs which predispose a woman to breast 
cancer have any influence on prognosis, with only one exception which is the SNP located 
at 8q24(280) - first identified by Easton et al(96).  There has been a small amount of work 
which looked at the relationship between polymorphisms encoding interleukins and breast 
cancer survival.  This same study also looked at the relationship between a number of these 
polymorphisms and environmental prognostic factors to look for any possible 
interactions(281).  They did find several significant interactions between two SNPs in IL23R 
and a lower Native American ancestry and breast cancer specific survival.  However, this 
study was conducted in a largely African-American and Hispanic population who have 
already been shown to have a poorer outcome than Caucasian women.  Additionally the 
majority of breast cancer data is based on Caucasian populations.  The lack of data in this 
area may be down to a multitude of factors, including the lack of knowledge into the 
genetics underlying prognosis, lack of current research in the field and publication bias.  
The role of gene-environment interactions in breast cancer outcome is poorly understood 
at this moment of time and further work is required in this area.  Once again future 
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research may provide a greater understanding of disease and may add to the prediction of 
patient prognosis. 
From the literature there is an argument that, with the exception of prior HRT use, sensible 
advice on healthy lifestyle choices including a healthy diet, exercising and keeping within 
the normal BMI range is the best advice that can be offered women diagnosed with breast 
cancer to improve their outcomes.  There are once again indications that the 
environmental factors which affect risk also play a role in prognosis.  For example a high 
post-menopausal BMI is associated with an increased risk and a poorer prognosis; the 
reason for this may be that the increased circulating oestrogen increases risk and results in 
a poorer outcome. Therefore once again it could be postulated that ESR1 and FGFR2 
polymorphisms may have a negative effect on prognosis too or gene-environment 
interactions may also influence prognosis.  This is a potentially interesting future field of 
research which could also result in elucidation of pathogenic mechanisms and novel 
therapeutic breakthroughs.       
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Breast Cancer Survival and 
Deprivation  
1. Introduction 
As mentioned in the previous chapter the incidence of breast cancer is increasing 
worldwide(1); it is because of this high incidence of disease that there has been such 
extensive work carried out to assess various risk and prognostic factors which contribute to 
its development.  For example women from the most deprived areas (or low SES) have 
been found to have a poorer outcome than those from more affluent areas (or SES).  
However the reason for this disparity between those in high and low socioeconomic groups 
remains unknown – it has been suggested it may relate to later presentation, lower 
awareness of the disease, poor access to treatment or biological factors(273,282–284). 
One such large scale study investigating cancer survival throughout Europe is the 
EUROCARE project, which has recently published its most up to date results in EUROCARE-
5(285).  The most recent results found the European mean 5 year survival for breast cancer 
to be 81.8% (95% CI; 81.6% - 82.0%).  This was unfortunately considerably lower in the UK 
and Ireland at 79.2% (95% CI; 79.0%-79.4%) 5 year survival(285).  There are various possible 
reasons for the lower survival in the UK including population health, access to care, 
screening, social and lifestyle factors.  However, when looking at this type of data it is 
always important to approach the results with a certain level of caution as there are many 
incomplete cancer registries in some of the major Europeans countries – including France, 
Germany and Italy.  The health of the population within in these blank spots is unknown, 
which may result in an over or under estimation of survival in that country.  In addition, 
EUROCARE fails to take into account other sociodemographic and environmental factors 
which have been demonstrated by the evidence in the previous chapter to influence 
outcomes(286). 
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In light of the proposed association between low SES and lower mean survival, it was of 
interest to assess survival in a smaller Scottish cohort who had all been diagnosed in 
Tayside between 2000 and 2004.  The aim of this survival analysis was to look at survival as 
a whole in Tayside to allow comparison with large studies like EUROCARE-5 and smaller 
studies which have investigated survival in other populations.  In addition, it aims to 
investigate the impact of key prognostic factors on survival, including some of those 
previously mentioned.  These prognostic factors include deprivation, tumour stage at 
diagnosis, oestrogen receptor status (ER), progesterone receptor status (PR), human 
epidermal growth factor (HER2) receptor status and age.  Socioeconomic status was the 
only environmental risk or prognostic factor which was taken into account when this 
dataset was collected.  Therefore this unfortunately means that analysis of the other 
environmental and genetic factors discussed in the previous chapters, such as BMI, HRT or 
HBC use, cannot be assessed in this analysis; however this is something which would be of 
interest to pursue in this future. 
2. Method of Analysis 
The data from 1851 women diagnosed with primary breast cancer in Tayside was collected 
between 2000 and 2004.  Anonymised information was collected on date of diagnosis, 
patient age at diagnosis, grade, tumour size, lymph node status, ER, PR and HER2 status, 
treatment, specific subtype of cancer and the postcode at time of diagnosis.  The 
pathological parameters were collected and recorded by a single team of pathologists 
based in Ninewells hospital.  All the patients were managed by the same multidisciplinary 
team.  These patients were then followed up until December 2013 with information on 
survival collected from medical records and death certificates.  For those participants 
known to have died the cause of death was obtained from the death certificates.  Outcome 
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was recorded as alive, recurrence and date of this, or date of death with the specific cause 
of death also recorded. 
The data was then analysed using SPSS(287), which allowed the calculation of life tables, 
Kaplan-Meier plots and Cox regression analysis for all the various factors included in 
analysis.  Kaplan-Meier analysis and Life tables where used to calculate 5 and 10 year 
cumulative survival rates, quoted with 95% confidence intervals (CI) and standard errors 
(SE) respectively.  For further information on risk cox regression analysis was used to 
calculate hazard ratios (HR) quoted with 95% CI, which also allowed various co-variants to 
be included in analysis. 
Three outcomes were used for each analysis All-Cause Mortality (death by any cause 
including breast cancer), Breast Cancer Specific Mortality (the cause of death was 
confirmed by the death certificate) and Disease Free Survival (recurrence was recorded in 
medical records).  Each outcome was analysed to determine if any of the prognostic factors 
influenced it; these included age, deprivation, tumour size (mm), invasive grade, nodal 
status, tumour type and ER, PR, and HER2 status. 
Age was divided into three age categories with reference to the screening program - groups 
<50 years (pre-screening), 50-69 years (screening) and ≥70 years (post-screening) – for data 
analysis.  Tumour size was also analysed with the women divided into groups, based on the 
T1, 2 and 3 staging system used in Tayside - ≤20mm, 20 - <50mm, ≥50mm.   
Finally, deprivation was classified using the patient’s postcode at diagnosis and the 2001 
Carstairs index(288).  Carstairs classifies postcode areas into 10 deprivation categories 
dependent on a number of factors including overcrowding, number of cars, male 
unemployment and social class based on the 2001 census.  As the data set was collected in 
the period around 2001 using this measure of deprivation was deemed the best option, as 
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it was up to date for this cohort.  For this analysis postcodes were divided into 10 
deprivation deciles, but due to small numbers of women in some groups the deciles were 
then grouped into 3 SES categories: affluent -deciles 1 and 2; intermediate - deciles 3-7; 
deprived – deciles 8-10.  These groups were divided simply to try and divide the women in 
such a way there were numerically similar group sizes. Additionally, to eliminate any bias 
caused by the division of the groups in this way the top 3 and bottom 3 groups were 
compared to look for any survival differences across all outcomes. 
Figure 4.1 Kaplan Meier Plots illustrating how survival over time for each survival outcome for both all cancers 
and operable cases only i)All Comers (operable and inoperable) and ii) operable cancers only. A) All-Cause 
mortality; B) Breast Cancer Specific Mortality; C) Disease Free Survival.   
B. A. C. 
i)All Comers 
ii)Operable Cancers Only 
A. B. C. 
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3. Results 
All 1851 women had a primary breast cancer and were therefore included in the analysis, 
unless there were missing values for a particular analysis.  Over a median follow up period 
of 8.8 years, which ranged between 0-13.9 years, there were 768 deaths and 342 of these 
were breast cancer specific deaths identified from death certificates at the national records 
in Edinburgh.  In the same time period of approximately 8 years there were 405 
recurrences of breast cancer, identified from medical records.   
3.1 Five and Ten Year Survival  
Survival was assessed both in all cancers (all invasive and in situ lesions) and operable 
cancers only, the latter to allow comparison with other studies as they generally only 
include operable cases.  Initially survival in all cancers was assessed for 5 and 10 year 
survival across all 3 outcomes.   
Breast cancer specific survival was higher at both 5 and 10 years than all-cause mortality 
when all cancers were included in analysis (Table 4.1 and Figure 4.1) and when survival was 
calculated using both life tables and Kaplan-Meier analysis.  Five year survival was 82% (+/- 
1%) for breast cancer specific mortality and was only 70% (+/-1%) for all-cause mortality.  
These survivals were lowered at 10 years to 76% (+/-1%) for breast specific mortality and 
56% (+/-1%) for all-cause mortality. 
Disease free survival shows similar cumulative survival rates to those of breast cancer 
specific mortality; at 5 years it was 80% (+/- 1%) and at 10yrs it was 75% (+/- 1%) for all 
cancers (Figure 4.1).  A second analysis was performed excluding the 168 cases of ductal 
carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) these failed to significantly 
alter cumulative survival rates, and so it was decided to continue the analysis with them 
included.   
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Variable 5 year Cumulative Survival (% +/-SE) 10 year Cumulative Survival (5 +/- SE) 
All-Cause  Breast 
Cancer 
Specific  
Disease Free 
Survival 
All-Cause  Breast 
Cancer 
Specific  
Disease Free 
Survival 
All Patients 70% (+/-1%) 82% (+/- 1%) 80% (+/- 1%) 56% (+/-1%) 76% (+/- 1%) 75% (+/- 1%) 
Operable 
Patients 
80% (+/-1%) 87% (+/-1%) 84% (+/-1%) 66% (+/-1%) 82% (+/-1%) 78% (+/-1%) 
Age       
 <50yrs 80% (+/- 2%) 82% (+/- 2%) 75% (+/- 2%) 69% (+/- 3%) 75% (+/- 3%) 68% (+/- 3%) 
50-69yrs 83% (+/- 1%) 88% (+/- 1%) 85% (+/- 1%) 71% (+/- 2%) 84% (+/- 1%) 80% (+/- 1%) 
>70yrs 46% (+/- 2%) 77% (+/- 2%) 76% (+/- 2%) 26% (+/- 2%) 64% (+/- 3%) 69% (+/- 2%) 
Deprivation       
Affluent 74% (+/- 2%) 84% (+/- 2%) 81% (+/- 2%) 58% (+/- 2%) 78% (+/- 2%) 76% (+/- 2%) 
Moderate 73% (+/- 2%) 85% (+/- 1% ) 82% (+/- 2%) 60% (+/- 2%) 78% (+/- 2%) 77% (+/- 2%) 
Deprived 63% (+/- 3%) 75% (+/- 2%) 76% (+/- 2%) 49% (+/- 3%) 71% (+/- 3%) 70% (+/- 3%) 
Nodes       
Negative 77% (+/- 1%) 89% (+/- 1%) 87% (+/- 1%) 63% (+/- 2%) 84% (+/- 1%) 84% (+/- 1%) 
Positive 65% (+/- 2%) 73% (+/- 2%) 67% (+/- 2%) 49% (+/- 2%) 64% (+/- 2%) 58% (+/- 2%) 
Invasive 
Grade 
      
1 84% (+/- 2%) 96% (+/- 1%) 97% (+/- 1%) 72% (+/- 3%) 92% (+/- 2%) 92% (+/- 2%) 
2 74% (+/- 2%) 86% (+/- 1%) 83% (+/- 2%) 58% (+/- 2%) 79% (+/- 2%) 76% (+/- 2%) 
3 63% (+/- 2%) 71% (+/- 2%) 67% (+/- 2%) 49% (+/- 2%) 65% (+/- 2%) 62% (+/- 2%) 
Size (cm)       
≤2cm 87% (+/- 1%) 94% (+/- 1%) 91% (+/- 1%) 73% (+/- 2%) 89% (+/- 1%) 86% (+/- 1%) 
2-5cm 73% (+/- 2%) 80% (+/- 2%) 75% (+/- 2%) 56% (+/- 2%) 73% (+/- 2%) 69% (+/- 2%) 
>5cm 58% (+/- 5%) 66% (+/- 5%) 58% (+/- 5%) 41% (+/- 5%) 56% (+/- 5%) 48% (+/- 5%) 
ER Status       
Positive 76% (+/- 1%) 87% (+/- 1%) 84% (+/- 1%) 60% (+/- 2%) 80% (+/- 1%) 78% (+/- 1%) 
Negative 56% (+/- 3%) 64% (+/- 3%) 59% (+/- 3%) 46% (+/- 3%) 59% (+/- 3%) 57% (+/- 3%) 
PR Status       
Positive 78% (+/- 1%) 88% (+/- 1%) 86% (+/- 1%) 61% (+/- 2%) 82% (+/- 1%) 79% (+/- 1%) 
Negative 61% (+/- 2%) 71% (+/- 2%) 66% (+/- 2%) 50% (+/- 2%) 65% (+/- 2%) 64% (+/- 2%) 
HER2 
Status 
      
Negative 74% (+/- 
1%)* 
84% (+/- 
1%)* 
81% (+/- 1%) 57% (+/- 
2%)* 
77% (+/- 
1%)* 
74% (+/- 1%) 
Positive 67% (+/- 
3%)* 
77% (+/- 
2%)* 
72% (+/- 3%) 58% (+/- 
3%)* 
73% (+/- 
3%)* 
69% (+/- 3%) 
Table 4.1 – Summary of all cumulative 5 and 10 year survival rates calculated for all variables investigated by 
life tables (* insignificant log rank test). 
A second analysis was carried out which included only the 1542 operable breast cancer 
cases in the cohort to provide 5 and 10 year cumulative survivals which are comparable to 
other published data.  This meant that the 5 and 10 year survival rates were increased 
when compared to that of all cancers; 5 year survival for all-cause survival increased by 
10% to 80% (+/-1%) and breast cancer specific survival to 87% (+/-1%)(Table 4.1 and Figure 
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4.1ii).  This increased survival is to be expected as women with operable cancer by 
definition have a better prognosis and are generally more medically fit.   
The relationship between all-cause mortality and survival is linear in both the all cancers 
and operable cancers analyses.  Whereas the relationship between breast cancer specific 
cancer mortality and survival is curved indicating that the chance of surviving breast cancer 
increases as the time from diagnosis increases.  The difference between all-cause and 
breast cancer specific survival was the same in for both all cancers and operable cancers.  A 
similar curved relationship is seen between recurrence and time, which reflects that the 
highest chance of recurrence is within the first 5 years after diagnosis 
3.2 Survival and Year of Diagnosis 
The women in this cohort were recruited between 2000 and 2004, and so separate analysis 
A B 
C 
Figure 4.2 Kaplan-Meier plots showing survival 
by year of diagnosis - A) All-Cause Mortality, B) 
Breast Cancer Specific and C) Disease Free 
Survival.  There was no significant difference 
seen between groups for any outcome.  
The key at the side denotes the colour and 
corresponding year of diagnosis. 
2000 
2001 
2002 
2003 
2004 
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was carried out to identify any improvement in survival dependent on the year of 
diagnosis.  The hypothesis being that women diagnosed in 2004 have a better outcome 
than those diagnosed in 2000.  The cohort was therefore divided into 5 groups dependent 
on the year they were diagnosed.  This initial Kaplan-Meier analysis failed to show any 
significant difference between year of diagnosis and survival across all outcomes (Figure 
4.2). 
Therefore, a univariant cox regression analysis was undertaken to look for any associations 
between the year of diagnosis and survival (Table 4.2).  This once again failed to identify 
any significant relationship between the year of diagnosis and any of the three outcomes.  
However, there was an insignificant trend towards increased survival (p >0.05) between 
2000 and 2004 for both breast cancer specific survival and disease free survival (Table 4.2).  
This suggests there may be an improvement in survival over this time, which is not 
significant due to small numbers and short time period of recruitment used. 
 Unadjusted Hazard Ratios 
(95% CI) 
P value 
All-Cause Mortality 
2004 1.00 0.4 
2000 0.97  (0.78-1.20) 
2001 0.82  (0.65-1.03) 
2002 0.92  (0.73-1.16) 
2003 0.98  (0.78-1.23) 
Breast Cancer Specific Mortality 
2004 1.00 0.63 
2000 1.28  (0.93-1.77) 
2001 1.16  (0.84-1.61) 
2002 1.24  (0.88-1.73) 
2003 1.19  (0.85-1.65) 
Disease Free Survival 
2004 1.00 0.74 
2000 1.11  (0.82-1.51) 
2001 0.997  (0.73-1.37) 
2002 1.10  (0.80-1.52) 
2003 1.20  (0.88-1.62) 
 
Table 4.2 – Univariant cox regression analysis for each outcome by year of diagnosis.  The hazard ratios failed 
to be significantly different for one another; however there appeared to be a trend for increasing survival 
between 2000 and 2004 when looking at breast cancer specific mortality. 
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3.3 Survival, Stage and Receptor Status 
Tumour stage is defined as the size, invasive grade and lymph node status of the tumour; 
all of these factors are already associated with breast cancer outcome.  The influence of 
these factors was assessed in this cohort to confirm that these factors have the expected 
relationship with survival.  These results do confirm that positive nodal status, large 
tumours and high invasive grade are all associated with a significant decrease in 5 and 10 
year survival for both all-cause mortality and breast cancer specific mortality (log rank test - 
p <0.0001)(Table 4.1; Figure 4.3). 
Receptor status has also been previously associated with prognosis, this may be in part due 
to the fewer number of treatment options available for ER and PR negative tumours.  In 
this cohort ER and PR negative tumours were associated with a lower 5 and 10 year survival 
for all outcomes (log rank test – p<0.0001) (Figure 4.4i and ii).   
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A C B 
i)Tumour Size 
A C B 
ii) Invasive 
Grade 
A B C 
iii) Nodal Status 
Figure 4.3 - Kaplan-Meier Analysis of survival and tumour size, invasive grade and nodal status for each outcome: A) All-
Cause, B) Breast Cancer Specific and C) Disease Free Survival.  All the relationships reached significance on the log rank test 
(p< 0.0001). 
At the side of each set of plots the colour and corresponding variable are coded in a key. 
≤20mm 
20-50mm 
>50mm 
1 
2 
3 
Negative 
Positive 
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On the other hand, there was a no association found between  HER2 (human epidermal 
growth factor receptor) status and all-cause mortality or breast cancer specific mortality 
Figure 4.4 - Kaplan-Meier analysis of survival and receptor status for all three outcomes: A) All-Cause mortality, B) Breast 
Cancer Specific mortality and C) Disease Free Survival.  The relationship between ER/PR status (I and ii) and all three 
outcomes was significant (log rank test), but only the disease free survival outcome had a significant relationship between 
survival and HER2 status (iii).   
At the side of each set of plots the colour and corresponding variable are coded in a key. 
A B C 
i)ER Status 
A B 
C 
ii) PR Status 
iii) HER2 Status 
A B C 
ER – 
ER+ 
PR – 
PR+ 
HER2 – 
HER2 + 
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survival outcomes (log rank test p<0.05).   However, there was a significant increase in 
recurrence associated with HER2 positive cancers – 5 year disease free survival in women 
with HER2 negative cancers was 81% (+/-1%) and for positive cancers was 72% (+/-
3%)(Table 4.1; Figure 4.4iii). 
3.4 Age and Survival  
Previously, there has been an association made between breast cancer survival and 
age, which is thought to be for a number of reasons.  It was also suggeste d by the 
authors of the EUROCARE study that survival in the older UK population may partly 
explain the difference in 5 year survival between the UK and Europe(285).  Therefore, 
women were divided into groups by age which reflected the UK screening program - 
<50 years, 50-69 years and >70 years.   
It was found that women in the oldest groups had the lowest all -cause and breast 
cancer specific survival (Table 4.1).  The women who were <50 or 50-69 years old had 
similar all cause survival, but women in the <50 years group have a slightly lower 
breast cancer specific survival – 5 year survival in those <50 years was 82% (+/-2%) 
compared to those between 50-69 years which was 88% (+/-1%)(Figure 4.5).   
The women in the oldest and youngest groups both have worse disease free survival 
than those of screening age (Figure 4.5C): 5yr survival 75%, 85% and 76% for women 
<50, 50-69 and >70 respectively (p <0.0001).  Both the lower breast cancer specific survival 
and disease free survival in the pre-screening group may represent a number of things, 
including both more aggressive subtypes of tumour in these women and a later stage of 
presentation. 
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Unadjusted cox regression 
analysis confirmed these 
relationships, demonstrating that 
women in the >70 years groups 
have the highest risk of both all-
cause mortality and breast cancer 
specific death (Table 4.3).  
Women under 50 years old had 40% 
decreased risk of breast cancer 
specific death compared to those 
over 70 years (p = 0.0002).  Women 
in the screening group had a 61% 
decreased risk of breast cancer 
death (p<0.0001), but these values 
were less than that of all-cause 
mortality – 50-69 years HR of 0.25 
(95% CI; 0.22-0.30) and <50 years 
HR of 0.28 (95% CI; 0.22-3.4) when 
compared to >70 years.  When 
disease free survival was examined 
in the same way women in both 
>70 year and <50 year old groups 
have an increased risk of 
recurrence; but women in the 
screening group have a decreased 
A* 
B* 
C* 
Figure 4.5 - Kaplan-Meier plots depicting the relationship 
between age and survival, all three relationships were significant 
(log rank p<0.05). A) all-cause mortality has far lower survival in 
women over 70 years. B) In the breast cancer specific mortality 
group the 50-69 year group have the best survival and the >70 
years the worst.       C)  In the disease free survival group both the 
<50years and >70 years have the highest recurrence rate. 
<50 yrs 
50-69 yrs 
>70 yrs 
108 
 
risk (HR = 0.57 (95% CI; 0.46-0.72; <0.0001)(Table 4.3). 
A multivariant cox regression model was then used to analyse if deprivation, tumour size, 
invasive grade or nodal status had confounded these results (Table 4.3). The relationship 
between age and all-cause and breast cancer specific mortality remained significant 
(p<0.001) when adjusted for these confounding factors.  Therefore these factors do not 
influence the relationship between age and all-cause mortality in these cases, and thus 
age is an independent risk factor for all-cause mortality. 
Breast cancer specific mortality remains significant between the age groups after 
adjustment.  However, there is an increase in risk of breast cancer specific mortality in the 
screening group between the adjusted and unadjusted.  The HR is 0.39 (95% CI; 0.31-0.49) 
in the unadjusted analysis and 0.69 (95% CI; 0.51-0.95) in the adjusted screening group 
(Table 4.3); which suggests that one of the factors adjusted for contributes to the increased 
survival in these women. When the analysis was adjusted, women in the pre-screening 
group have a lower risk of breast cancer specific death than the screening group (40% vs 
31%).  This observed difference between the two may be due to stage at diagnosis, which is 
lower in the screening women, or deprivation. 
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Table 4.3 - Cox regression analysis by age for all three outcomes.   
* Significant.  
 
a 
Adjusted for deprivation, size, grade and nodal status. 
 
The relationship between age and disease free survival lost its significance when the 
analysis was adjusted for the above factors.  Women in the screening group no longer 
had a decreased risk of recurrence when compared to those in the post-screening 
group HR = 0.86 (95% CI 0.64-1.15; p = 0.53) (Table 4.3).  To further analyse the influence 
of the factors adjusted for on this relationship between disease free survival and age, 
each confounding factor was removed from the analysis individually and the effect on 
the HR significance observed.  This showed that when information on stage (tumour 
size, grade and nodal status) was removed from the analysis then the significant 
relationship returned.  This suggests that deprivation and age are independent risk 
factors, but there is a difference in stage between these women which accounts for 
the difference in disease free survival.  This may relate to women of screening age 
being diagnosed with lower stage cancers as they are picked up earlier than women of 
pre- and post- screening age.   
 
Unadjusted 
Analysis 
All-Cause Mortality Breast Cancer Specific 
Mortality 
Disease Free Survival 
 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
>70yr 1.00 <0.0001 1.00 <0.0001 1.00 <0.0001 
 <50yrs 0.28 (0.22-
3.4)* 
0.60 (0.46-
0.79)* 
1.00 (0.78-1.30) 
50-69yrs 0.25 (0.22-
0.30)* 
0.39 (0.31-
0.49)* 
0.57 (0.46-0.72)* 
Adjusted 
Analysis
 
 
 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
>70yr 1.00 <0.0001 1.00 0.01 1.00 0.53 
<50yrs 0.31 (0.24-
0.41)* 
0.60 (0.42-
0.85)* 
0.85 (0.62-1.18) 
50-69yrs 0.39 (0.31-
0.48)* 
0.69 (0.51-
0.95)* 
0.86 (0.64-1.15) 
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3.5 Socioeconomic Status and Survival 
Socioeconomic status was calculated using the Carstairs index(288), which separated 
the women into 10 groups depending on postcode at diagnosis.  The Carstairs  index 
was chosen in this instance as it combines 4 indicators of disadvantage to give an 
indication of deprivation and it was based on the 2001 census data, which is relevant 
as this data was collected between 2000 and 2004.  However it was found that in some 
of the deciles there were few participants and even fewer events, therefore it was not 
suitable to analyse the data in these ten groups.  For this reason these ten groups 
were divided into three groups: affluent (n=590 women), moderate (n=719 women) 
and deprived (n=369 women).  This demonstrates that more women with a higher SES 
are diagnosed with breast cancer, than those with a lower SES.  Upon comparison it 
was observed that there was a significant difference in survival between groups for all 
3 outcomes (log rank tests – all-cause p = 0.002; breast cancer specific p = 0.007; disease 
free survival p = 0.035)(Figure 4.6).  In each of the outcomes there was little difference 
observed between women in the affluent and moderate groups (Table 4.1), but 
women in the deprived group had consistently poorer outcomes.  For example, 
women in the affluent and moderate SES groups had a cumulative 5 year breast cancer 
survival of 84% (+/-2%) and 85% (+/-1%) respectively.  However, women in the 
deprived group had a 5 year survival of 75% (+/-2%) (Table 4.1).  In general, it was 
noted that there was a 10% difference in 5 years survival between deprived women 
and those in the higher SES groups across all outcomes (Figure 4.6).  This relationship 
is perhaps more pronounced in the all-cause mortality outcome, which suggests that 
women in the most deprived group are more likely to die but that this death may not 
necessarily be a breast cancer specific death.   
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This analysis was then replicated using the women in the top 3 and bottom 3 deciles; 
to negate any bias which may have been caused by division into 3 SES groups ( Figure 
4.6ii).  This confirmed the results of the previous analysis with a significant difference 
on Kaplan-Meier log rank testing between the most affluent and most deprived being 
observed across all three outcomes in analysis (log rank tests – all-cause p = 0.002; breast 
cancer specific p = 0.003; disease free survival p = 0.016) (Figure 4.6ii).  
As with age this analysis was taken further using both univariant and multivariant cox 
regression analyses to look at the risk associated with deprivation and breast cancer  
outcome.  The univariant analysis of the three SES groups found that women in the 
affluent group had a 31% decreased risk of breast cancer specif ic death compared to 
those in the most deprived group (HR = 0.69; 95% CI 0.52-0.90; p = 0.007)(Table 4.4).  
These women also hava a 25% decreased risk of all-cause mortality compared to the most 
deprived women (HR = 0.75; 95% CI 0.62-0.9; p = 0.004).  Women in the moderate SES 
category had similar survival to those in the affluent group across all outcomes (all-cause 
HR = 0.74; breast cancer specific mortality HR = 0.68, and disease free survival HR = 0.73).  
Disease free survival was also significantly (p = 0.036) better in women who fell into the 
affluent and moderate categories when compared to deprived women (Table 4.4). 
When these results were adjusted for age, tumour size, grade and nodal status there 
was a change in the significance of these relationships.  The significant difference 
between affluent and deprived groups was lost across all outcomes; however a 
significant relationship between the moderate and deprived groups remained (Table 
4.4). To further analyse these results, as with the analysis for age, the confounding 
factors were removed one by one from the analysis and the results observed.  When 
tumour size, grade and nodal status were removed from the analysis the significant 
difference between the affluent and deprived groups returned.  This suggests that 
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there is a difference between tumour stage at diagnosis, which influences the 
difference in survival associated with deprivation. 
The multi-variant cox regression was also carried out on the top and bottom deciles.  
The adjusted analysis failed to find any significant survival between affluent and 
deprived women for breast cancer specific mortality (HR = 0.74; 95% CI: 0.54-1.02; 
p=0.064) or disease free survival (HR = 0.86; 95% CI: 0.65-1.16; p=0.33)(Table 4.4).  
Further analysis demonstrated that the reason for the loss of the significant difference 
Figure 4.6 Deprivation analysis Kaplan-Meier plots. i) Deciles grouped in to the categories affluent (1,2), moderate (3-
7) and deprived (8-10).  All three outcomes A) All-cause mortality, B) Breast cancer specific mortality and C) Disease 
free survival has significant results on log rank testing. ii) The final group are the top deciles versus the bottom 
deciles, all three were significant on Log rank testing.  
B A C 
i) Deprivation Categories – Affluent, Moderate, Deprived 
ii) Deprivation 1-3 versus 8-10 
A B C 
Affluent 
Moderate 
Deprived 
High SES 
Low SES 
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was due to the inclusion of staging information; once again demonstrating that stage 
is responsible for the difference observed between women with a high and low SES 
(Appendix 4).  
Unadjusted 
Analysis 
All-Cause Mortality Breast Cancer Specific 
Mortality 
Disease Free Survival 
 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Deprived 1.00 0.003 1.00 0.007 1.00 0.036 
Affluent 0.75 (0.62-0.91)* 0.69 (0.52-
0.90)* 
0.75 (0.58-
0.98)* 
Moderate 0.74 (0.61-0.89)* 0.68 (0.53-
0.89)* 
0.73 (0.56-
0.94)* 
Adjusted 
Analysis
a 
 
 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P 
value 
Deprived 1.00 0.15 1.00 0.01 1.00 0.037 
Affluent 0.80 (0.62-1.03) 0.86 (0.62-1.20) 0.98 (0.72-1.34) 
Moderate 0.70 (0.55-0.89)* 0.62 (0.45-
0.85)* 
0.72 (0.53-0.97)* 
 
Adjusted 
Analysis
a 
 
 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P 
value 
1-3 Vs 8-10 0.75 (0.59-0.95)* 0.017 0.74 (0.54-1.02) 0.064 0.86 (0.65-1.16) 0.33 
Table 4.4 - The Cox regression analysis by deprivation category for all three outcomes.   
* Significant.  
a 
Adjusted for age, size, grade and nodal status. 
 
The significant difference between the risk of all-cause mortality between the two SES 
groups after adjusting for potential co-founding factors remained – HR = 0.75 (95% CI: 0.59-
0.95; p = 0.017).   Therefore, women in the affluent group have a 25% decrease in risk of 
dying of any cause in comparison to women in the most deprived groups.  This suggests 
that deprivation is an independent risk factor for all-cause mortality in women diagnosed 
with breast cancer.  
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4. Discussion 
4.1 Overall Trends in Survival 
The results of this analysis on a Tayside cohort confirmed the associations between 
tumour size, grade, nodal status and receptor status with breast cancer outcome. In 
addition, this has highlighted the relationship between survival age, deprivation and 
year of diagnosis for the three outcome measures used.   
An earlier study by Twelves et al(283) found the 5 year survival of Scottish women 
diagnosed in 1987 to be 70.9% (95% CI; 68.6-73.1).  A later study published in 2001 
showing the 10 year survival in the same cohort found the survival to be 52.7% (95% 
CI; 50.3-55.1)(275).  A third study which aimed to compare the survival of this 1987 cohort 
to that of a 1993 cohort found that women diagnosed in 1993 had over a 10% increase in 8 
year survival from 57.4% to 68.3%(289).  This highlights that there has been a trend 
towards increasing survival in the past, which has been predicted to be equivalent to an 
annual decrease in mortality of 1.8% between 1997 and 2006 in a Spanish population(290). 
To allow comparison to other Scottish studies and EUROCARE-5, the all-cause mortality 
analysis was performed with all inoperable cases excluded.  This demonstrated that for 
women diagnosed in Tayside between 2000 and 2004 there was a 5 year cumulative 
survival for all-cause mortality in operable cases of 80% (+/- 1%) and 10 year survival was 
66% (+/-1%).  This is a 10% improvement in 5 year survival when compared to women 
diagnosed in 1987 and a 13% improvement in 10 year survival(283).  When comparisons 
are drawn to the 8 year survival of both the 1987 and 1993 cohorts, which were 57.4% and 
68.3% respectively(289), the 8 year survival was 72% (+/-1%); which shows there has been 
further improvements made in the survival of operable cancers over the past decade.   
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EUROCARE-5 found the UK and Ireland mean 5 year all-cause mortality survival to be 78.5% 
for operable cases, which was lower that the European mean of 82%(285).  In this Tayside 
cohort survival was higher than the UK and Ireland average as predicted by EUROCARE and 
more comparable with the European average at 80%.   
The 5 year survival for breast cancer specific mortality in previous literature has been found 
to be 81.6% in Scottish women diagnosed between 1986 and 2000(276).  In this study it 
was found that the 5 year breast cancer specific survival was 82%, which indicates that 
there has not been any significant improvement in breast cancer specific survival over the 
last decade.  This is in agreement with the lack of improvement noted when analysing the 
cases dependent on year of diagnosis, which failed to show any significant relationship 
(Table 4.2).  However, there was an indication that there may be a trend towards improving 
survival for breast cancer specific mortality; women diagnosed in 2000 had a 28% increase 
in risk of dying of breast cancer compared to those diagnosed in 2004.  This is consistent 
with published literature which found an estimated percentage change in breast cancer 
specific mortality to be 2% between 1993 and 2003(291).  However, the failure of the 
current analysis to reach significance may reflect the relatively small numbers of patients 
diagnosed each year in Tayside and that only a short time period was investigated (2000-
2004).   
This analysis also demonstrated that there was a 10% difference between all-cause 
mortality and breast cancer specific mortality survival.  This suggests that women 
diagnosed with breast cancer are more likely to die of something other than breast cancer 
between 5 to 10 years after diagnosis.  All-cause mortality analysis shows that survival 
continues to fall from 70% to 56% between 5 and 10 years, but in the breast cancer specific 
mortality outcome survival begins to level out only falling from 82% to 76% over the same 
time period (Figure 4.1).  Disease free survival showed a similar relationship to breast 
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cancer specific survival, with the majority of recurrence events happening in the first 5 
years after diagnosis. 
4.2 Deprivation and Survival 
Inequalities in breast cancer survival are a well-documented phenomenon, with women 
who are from the most deprived SES groups having consistently worse 
outcomes(272,273,275,276,284).  In this cohort women in the most deprived group had a 
consistently poorer outcome regardless of the outcome measure being investigated – all-
cause mortality, breast cancer specific mortality and disease free survival.  When the 
analysis was adjusted for confounding factors such as stage and age the significant 
difference between the affluent and deprived group was lost.  This demonstrated that in 
this cohort at least part of the survival difference was related to tumour stage at diagnosis.  
This is a finding which has been previously suggested by other published data, which 
predicted that stage accounted for 28% of the deprivation gap(278).  That study found that 
women in the lowest SES had a 23% increase in risk of breast cancer specific death(278), 
whereas in this analysis the risk was found to be 31%.    
To remove bias that may have been caused by the division of Carstair deciles into 3 groups 
a second analysis was carried out comparing the top and bottom SES categories.  The 
results of this analysis were the same as that of the above analysis. With the exception of 
all-cause mortality which remained significantly different between the two groups once 
adjusted for stage and age.  Women in the most affluent SES group had a 25% decreased 
risk of all-cause mortality, the reason for this may relate to differences in health or social 
factors between the deprived and affluent populations.   
When assessing survival in the three groups the significant difference remained between 
the moderate and deprived groups after adjustment for stage and age.  The reason and 
significance of this finding is unknown, but it may relate to the division of the data into 3 
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groups as the moderate group was the largest.   Other potential explanations of this finding 
are the measure of deprivation used, awareness in this population group or biological 
factors.   
The survival analysis in this cohort demonstrates that there is a disparity in survival 
between women in the least and most deprived SES groups.  This relationship was found to 
be related to stage when breast specific mortality risk was being investigated, as observed 
by other studies(278,284).  This difference in stage at presentation may relate to multiple 
factors such as breast awareness, access to health care or participation in the screening 
programme.  However, this difference in survival may have other contributing factors out-
with the scope of this analysis, such as tumour biology, genetics(273,279), or awareness in 
the community(282). 
Unfortunately, there was no information on other environmental prognostic factors or any 
risk factors collected.  It may have been interesting to further investigate the effect of these 
factors in this group of participants.  In the future it would be of great interest to see if any 
of the other environmental or genetic risk factors, identified in this thesis, interact with the 
impact SES has on outcome.  This may be something to pursue in the future, but would 
require the inclusion of an extensive questionnaire and genotypes in a large group.  The 
current VPH-PRISM project, which is recruiting in Dundee has an in depth questionnaire; 
this questionnaire includes information on all the environmental risk and prognostic factors 
deemed to have strong supporting evidence by this thesis.  This cohort will therefore allow 
a more in depth analysis of these factors on survival after a period of follow up. 
This analysis demonstrates that deprived women have a worse outcome than women with 
a high or moderate SES (Figure 4.6), this effect was seen regardless of how SES was 
defined.  This association was lost when the analysis was adjusted for staging information; 
therefore poorer outcome in deprived women may be in part due to stage at diagnosis.  In 
118 
 
addition there are more women with a higher SES diagnosed with breast cancer in Tayside 
(affluent 35%, deprived 21%) this supports that a high SES is associated with increased 
breast cancer risk.  
4.3 Conclusion  
One of the strengths of this analysis is the data-set which is extremely complete and 
consistent.  The reasons for this include that the treatment was carried out by a single 
multidisciplinary team, the breast tissue and lymph node samples were analysed by a 
single team of pathologists.  Patients were followed up using both medical notes and  
death certificates, which meant that an accurate cause of death was identified in all 
patients.   Criticism may arise with regards to the inclusion of DCIS, LCIS and inoperable 
cancers in the analysis; however, this was done to give a clear indication of survival when 
all cases were included and not those picked for favourable characteristics.  Additionally, 
there may be questions as to why the dataset was split into the 3 risk groups – the reason 
for this was to try and split the participants as equally as possible.  In an attempt to control 
for this, the deprivation was analysed a second time to compare the top and bottom 
deciles.  This second analysis confirmed the results observed in the initial analysis, finding 
the same association between deprivation and poor outcome.   
These results from this cohort demonstrate an increasing survival in Scotland and Europe, 
with the majority of breast cancer deaths and recurrences happening within the first 5 
years after diagnosis.  These results also confirm that, as discussed in the previous chapter 
deprivation is associated with a poorer outcome.  Stage was identified as contributing to 
poorer breast cancer specific outcomes, but not to all-cause mortality.  The reason for this 
relationship between breast cancer and deprivation requires further research to elucidate 
why the two are linked.  However as previously demonstrated breast cancer risk and 
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prognosis are determined by a complex mixture of environmental, reproductive and 
genetic factors and, so to understand risk and prognosis requires a holistic approach.
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Conclusion 
 
When beginning this project there were several key questions which required answers in 
order to provide a different perspective on breast cancer pathogenesis; a different 
perspective which is more holistic and incorporates different elements of the disease.  Prior 
to being able to view this heterogeneous disease in a holistic manner, the information on 
the individual elements had to be assessed.  Therefore, a series of literature reviews were 
undertaken to gather the facts from the wealth of published literature available to come to 
conclusions about what contributes to breast cancer risk and survival.   
There have been a large number of studies published which investigate the many different 
aspects of epidemiological breast cancer risk.  From the current literature review it has 
been concluded that reproductive factors such as age at menarche, age at FFTP, parity, 
current HRT use, birth control use and age at menopause all contribute to breast cancer 
risk; most likely through a hormonally driven mechanism, which relates the developmental 
stage of the breast tissue.  In addition, other environmental risk factors exist including a 
high post-menopausal BMI, smoking, exposure to ionising radiation, alcohol consumption, 
ethnicity, socioeconomic status and mammographic density which all increase breast 
cancer risk via variety of mechanisms. 
Genetics also influence breast cancer risk; there are a combination of high and low risk 
genetic changes which contribute to the risk of developing breast cancer via a variety of 
mechanisms.  However, little is understood about how some genetic changes alter risk.  
The majority of breast cancer is a combination of various risk factors which add together to 
reach a disease threshold (50).   
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Additionally there is a growing amount of research being carried out on gene-environment 
interactions in breast cancer and how these may modify risk.  For example, there is 
emerging evidence that the risk associated with FGFR2 polymorphisms may differ 
depending on age at menarche, parity and a BMI>25 in post-menopausal women(226).  
This is particularly interesting as FGFR2 and the other implicated risk factors are all thought 
to exert their effect on risk via hormonal mechanisms.  It could therefore be hypothesised 
that these environmental and genetic risk and prognostic factors all work within the same 
cellular pathways.  These gene-environment interactions may exist as they target common 
pathways and by identifying these pathways more can be learned about breast cancer 
pathogenesis.  Gene-environment interactions also provides a framework of thinking to 
allow new breast cancer risk factors, both genetic and environmental, to be discovered. 
The work on gene-environment interactions is in its early stages with research failing to 
come up with conclusive evidence implicating a particular set of interactions.  However as 
of yet there seems to be a failure to use the knowledge about individual risk factors to 
target the research into gene-environment interactions, as suggested above.  Pathways 
which appear to underlie the mechanism of risk in multiple genetic and environmental risk 
factors are DNA damage and repair, cell cycle control, apoptotic processes, oestrogen 
signalling, the microenvironment and breast tissue development pathways.  Many of the 
factors come under more than one of these headings and they all have different roles to 
play in these wide biological process headings (Figure 5.1).  However, as stated during the 
genetics chapter, some genetic factors are also known to bind and interact; for example, 
ATM is needed to activate CHEK2.  
Another interesting point is that some of the environmental factors which influence risk 
also influence prognosis; these include BMI, weight loss, HRT use, and socioeconomic 
status. However, some factors were associated with better outcome despite being  
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associated with increased risk – such as high SES and HRT.  High BMI on the other hand was 
associated with an increased risk and poorer prognosis.  So once again there are common 
environmental factors involved in these processes and this may be due to common 
mechanisms at play.  However, it is also possible that prognostic factors are at least in part 
working by a different mechanism to affect outcome.  When deprivation was investigated 
in the Tayside cohort it was consistently associated with a poorer breast cancer specific 
outcome.  In part, this poorer prognosis was due to the effect of tumour stage, as those 
from a more deprived area appeared to have higher stage tumours.  The analysis also 
confirmed that ER negative, PR negative, lymph node involvement, older age, larger size 
and higher grade tumours were all associated with poorer outcome, as expected. As there 
Figure 5.1 - This is a diagrammatic representation of the biological mechanisms which are found to be associated with 
breast cancer risk.  In the centre are the biological mechanisms highlighted as having an involvement in breast cancer 
pathogenesis.  On the left are the environmental risk factors and on the right are the genetic risk factors.  A line connects 
the risk factors to the biological mechanism(s) which are thought to underlie how they alter breast cancer risk. 
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was no information on other environmental prognostic factors collected in this cohort 
analysing these in greater detail was unfortunately not possible.  In the future, the 
collection of information on further epidemiological parameters (reproductive risk factors, 
BMI, as well as SES) and genetic information on patients diagnosed with breast cancer 
would allow a study of their influence on prognosis and any gene-environment interactions 
in this context – the VPH-PRISM study may allow this.  
Another element which has not been covered in depth but is important in tumour 
behaviour and is potentially influenced by genetics, the environment and their interactions 
is the microenvironment(292).  This has already been touched upon when discussing 
genetic risk factors, as some of the low penetrance polymorphisms associated with risk - 
SLC4A7 and LSP1 - are involved in the regulation of the microenvironment.  The 
microenvironment itself consists of extra-cellular matrix and stromal tissue; this stroma 
consists of fibroblasts, adipocytes, pre-adipocytes, blood vessels, and inflammatory 
cells(293).  The stromal tissue and epithelial cells interact, and this interaction plays a role 
in the neoplastic processes of initiation, progression, invasion and angiogenesis(294)291).     
Breast stroma also plays a crucial role in the normal development of breast tissue.  This 
developmental process in women has a hormonally driven element and is also triggered by 
certain reproductive events in a woman’s life such as first full term pregnancy and 
breastfeeding.  This is a process which has been implicated in both environmental and 
genetic breast cancer risk.  The stroma is thought to provide the signals which encourage 
the breast epithelium to develop to maturity and this, in turn, provides a link between the 
stromal tissue and reproductive risk factors associated with breast cancer development.  If 
or how these two factors interact is unknown, but it provides an interesting area of 
research.  Additionally stromal factors may be linked to the added risk associated with 
increased breast density; one suggested reason as to why high density equates to high risk 
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is that there is an unknown factor which increases risk.  This unknown factor may well be a 
stromal factor, which increases risk and has caused a high breast density due to its 
interaction with surrounding tissues causing a higher density of epithelial tissue and 
collagen(296).   
Previous studies have found there to be differences in expression between normal and 
tumour associated stroma.  These differences have been hypothesised as being involved in 
these tumour-stromal interactions which could be potential pharmacological targets in the 
future(297,298).  Some examples of genes up-regulated in tumour associated stroma were 
GRAM1 and INHBA, both of which are members of the TGFβ family.  Other genes were 
found to be down-regulated in the tumour associated stroma such as WIF1 and SFRP1, 
both members of the WNT signalling pathway(296). 
Therefore it can be hypothesised that the genes up and down regulated in the reactive 
stroma and tumour tissue could include those already identified as risk factors and new 
novel genes which are part of the common pathways identified as involved in breast cancer 
risk and prognosis.  To test this hypothesis would require sampling breast tissue at three 
locations (tumour, peri-stromal area and normal stroma), RNA extraction and then 
microarray analysis.  A proof of concept experiment was carried out as detailed below in 
Appendix 5; however extraction of RNA from formaldehyde fixed paraffin embedded tissue 
(FFPE) yielded a suitable quantity of RNA products, which were unfortunately of too poor a 
quality to carry out any further experiments.  It was therefore concluded that a future 
experiment with fresh tissue would be the most suitable experimental methodology, but 
due to time constraints this will be out-with the scope of this current thesis (Protocol in 
Appendix 5).  
This thesis aimed to demonstrate that there are common biological mechanisms which 
underlie many of the genetic and environmental risk and prognostic factors that have been 
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associated with breast cancer.  There is not a single process involved and each risk factor 
may be involved in multiple pathways to contribute to risk or outcome.  Gene-environment 
interactions also exist and act to modify breast cancer risk, but there is still work to be done 
in this area to provide clarity.  A single factor can also act differently on risk and prognosis, 
such as deprivation which was shown to influence outcome in a novel analysis.  All of the 
above demonstrate that breast cancer is a complex heterogeneous disease, which can be 
best understood, not by looking at individual elements but by taking what is known about 
these elements and looking at them in a holistic way to inform future hypotheses and 
study. 
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APPENDICES 
Appendix 1. Search Terms Used in Medline for Genetic Risk Factors 
Genetic Risk Factor Search Terms : “Breast Neoplasms AND” 
BRCA1 BRCA1 
BRCA2 BRCA2 
ATM ATM 
CHEK2 CHEK2 
TP53 p53 
PTEN PTEN 
FGFR2 FGFR2 
TNRC9 (TOX3) TNRC9  
NOTCH2 NOTCH2 
ZNF365 ZNF365 
RAD51L RAD51L 
ESR1 ESR1 
CASP8 CASP8 
NEK10, SLC4A7 NEK10, SLC4A7 
MAP3K1 MAP3K1 
CDKN2A/B CDKN2A/B 
LSP1 LSP1 
COX11 COX11 
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Appendix 2. Search Terms Used in Medline for Environmental Risk Factors 
Environmental Risk Factor Search Terms : “Breast Neoplasms 
(aetiology and epidemiology) AND” 
Age at menarche and menopause  “Menarche” OR “Menopause” 
Age at FFTP and parity “Parity” or “Full term Pregnancy” 
Breastfeeding “Breastfeeding” 
Hormone replacement therapy and 
hormonal birth control 
“Hormone Replacement AE/ Contraceptives, 
Oral, Hormonal AE” 
Family History “Familial” 
BMI “Body Mass Index” 
Diet “Diet” OR “High Fat Diet” 
Alcohol Consumption “Alcohol Drinking/AE” 
Smoking “Smoking” 
Environmental Exposures "Environmental Exposure" 
Ionising Radiation “Radiation” 
Ethnicity and SES “Ethnicity” OR “Socioeconomic Status” 
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Appendix 3. Search Terms Used in Medline for Prognostic Factors 
Environmental Risk Factor Search Terms : “Breast Neoplasms AND 
Prognosis AND” 
Hormone replacement therapy and 
hormonal birth control 
“Hormone Replacement AE/ Contraceptives, 
Oral, Hormonal AE” 
BMI “Body Mass Index” 
Diet “Diet” OR “High Fat Diet” 
Alcohol Consumption “Alcohol Drinking/AE” 
Ethnicity and SES “Ethnicity” OR “Socioeconomic Status” 
Physical Activity “Physical Activity” OR “Exercise” 
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Appendix 4. Survival and Deprivation 
This table demonstrates the effect of removing each component of staging from the 
adjusted analysis and its effect on significance. 
 
 
All Cause BrCa Specific Disease Free Survival 
HR P value HR P value HR P value 
Nodes removed from analysis 
Deprived 1.00  1.00  1.00  
Affluent 0.77* 0.05 0.80 0.187 0.92 0.585 
Moderate 0.72* 0.008 0.62* 0.004 0.72* 0.034 
Size removed from analysis 
Deprived 1.00  1.00  1.00  
Affluent 0.77* 0.016 0.79 0.104 0.895 0.431 
Moderate 0.685* 0.0003 0.63* 0.001 0.73* 0.021 
All Staging info  removed from analysis 
Deprived 1.00  1.00  1.00  
Affluent 0.735* 0.002 0.69* 0.007 0.77* 0.05 
Moderate 0.68* 0.00005 0.66* 0.002 0.72* 0.013 
*Significant p <0.05 
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Appendix 5. Proof of Concept Molecular Analysis 
Fixed Tissue RNA Extraction 
As covered in the conclusion to further explore the relationship between the pathways 
involved in breast cancer the expression of genes which have been previously implicated 
breast cancer risk can be investigated in breast stroma, reactive stroma and breast cancer.  
One of the simplest ways to retrieve samples of stromal tissue would be to take cores from 
fixed tissue blocks.  However there is poor evidence that good quality RNA can be extracted 
from formaldehyde fixed paraffin embedded (FFPE) tissue.  It was for this reason that prior 
to starting tissue collection from participants for this study a proof of concept experiment 
was run with samples from Tayside tissue bank, to examine the quantity and quality of any 
RNA that could be extracted. 
Methods 
Samples were selected from Tayside tissue bank with the assistance of Dr Purdie, who 
selected three matched breast tumour and normal breast stroma from the tissue bank 
catalogue.  From the tissue blocks Dr Purdie marked an area from which the 1mm core was 
to be taken, chosen for their typical cellular characteristics.  1 mm cores were taken from 
these sites to allow for isolation of total RNA from the FFPE tissue using the Purelink FFPE 
Total Isolation Kit by Invitrogen.  There was a second elution taken of all samples during the 
washing stages of the extraction to ensure all the RNA extracted was collected.  These 
samples underwent analysis separately as the second elution samples in all later 
experiments.  This was followed by a DNase treatment using an Invitrogen kit on the 
extracted RNA. Each sample was named after the block from which the sample came 
followed by N or T for normal and tumour respectively (ICN, ICT, IET, IGT, ILN and INN). 
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The treated RNA was then quantified using the Invitrogen Qubit 2.0 Fluometer and the 
Qubit high sensitivity RNA assay using 2 µL of RNA per assay.  The quality of the RNA was 
also assessed using the Aligent R6K Screen Tape System Tape Station and the high 
sensitivity R6K kit. 
Two kits were used to allow comparison for the reverse transcription step: Reverse 
Transcription System by Promega and the High Capacity cDNA Reverse Transcription kit by 
Applied Biosystems.  The cDNA produced was stored at -20  ͦC, to do test RT-PCR 
experiments on at a later date if the RNA product was considered of a high enough quality. 
Any remaining RNA was stored at -80  ͦC for further use if necessary.  All practical work was 
carried out with the assistance of Dr Andrew Cassidy and Dr Desiree Rutschow in the 
Human Genetics Laboratory Ninewells Hospital. 
Results 
Samples came from three cases and for each case there was a tumour sample and matched 
normal sample.  These cases were case 1 ICN and ICT; case 2 INN and IET; and case 3 ILN and 
IGT.  After the RNA has been extracted the Invitrogen Qubit 2.0 Fluorometer with the high 
specificity RNA kit was used to try and quantify the amount of RNA present at a 1:100 
dilution.  The results are shown in the table below (Table 5.1), and it is clear that some 
samples in the 2nd elution failed to produce a measurable concentration of RNA.  Otherwise 
there was a wide range of results from 2.8 ng/µL to 86.0 ng/µL. These results indicate that 
from the fixed tissue RNA could be extracted, however the quantity was extremely 
variable. This may relate to the cellular content of the samples as the concentrations of 
RNA in normal stroma was considerably less than that of the tumour tissue, which is to be 
expected.    
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Case Sample Elution 1 (ng/µL) Elution 2 (ng/µL) 
1 ICN 2.80 - 
ICT 14.20 4.72 
2 INN 5.92 - 
IET 86.00 5.51 
3 ILN 16.20 2.87 
IGT 50.00 20.40 
Table 5.1 – The concentration of the extracted RNA as calculated by the Invitrogen Qubit 2.0 Fluorometer for 
both the first and second elution.  This shows there was a large range of RNA concentrations extracted. 
Once the RNA samples were quantified it was important to then check the quality of the 
RNA extracted, to do this the Aligent R6K Screen Tape Station was used.  This 
demonstrated that the extracted RNA was highly degraded and of poor quality failing to 
produce the desired bands at 18s and 28s.   
A second tape station was run for certain 
samples where there was still RNA for analysis, 
namely ICN, ICT, INN, IET, IGT and IET2 (2nd elution). 
These samples were run at a lower 
concentration of 1:20 dilution to try and further 
assess the quality of RNA.  Once again there was 
a failure to produce bands at 18s and 28s (Figure 
5.1). Additionally the RIN (RNA integrity 
number) values obtained were below the 
standard of 4 which is required for microarray 
analysis.  For these reasons it would not suitable for further use in either an RT-PCR or 
microarray analysis. 
Conclusion 
This therefore confirmed that though there was a high quantity of RNA extracted from 
some of these samples (Table 5.1), it was extremely degraded (Figure 5.1) and unusable.  
Additionally the optimum concentration of RNA needed for microarray is approximately 
IC
N
 IC
T
 IN
N
 IE
T
 IG
T
 IE
T2
 
Figure 5.1 - The results of the Aligent Tape 
Station which shows the extracted RNA is highly 
degraded; failing to produce bands at 18 and 28s.  
The accompanying RIN values are also shown. 
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100-300 ng per 3 µL, therefore adequate concentrations of RNA were only obtained in 2 of 
the above samples. The minimum RIN value requirement for microarray is also 4 and all of 
the samples failed to meet this quality measure across both analyses.  This meant that 
though a simpler way of obtaining samples, RNA extracted from fixed tissue was not 
suitable for the purpose of this experiment as it failed to produce a consistent product 
which was of adequate quantity or quality.  Therefore the decision was taken to explore 
alternative options for fresh tissue sample collection.  A second option is to use fresh 
frozen samples stored in an RNA preservative.  These samples shall allow the extraction of 
RNA, which is suitable for variety of methods of genetic analysis.  This will allow any 
alterations in expression between normal stroma, reactive stroma and breast tumour to be 
identified and analysed.  
Revised Protocol for Tissue Collection 
 Four suitable candidates shall be selected to have tissue samples for the purpose of 
genetic analysis.   
o Inclusion criteria: 
 Undergoing mastectomy,  
 ER and PR positive 
 HER2 negative  
 DNST 
 Core grade 2 or3  
 BIRADS breast density 2-4.   
o Exclusion criteria 
 Treated with neoadjuvant chemotherapy. 
 Potentially eligible participants identified at MDM 
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 Pre-prepared vials of RNA later labelled with study number, and T for tumour PT 
for peri-tumoural and N for normal stroma. 
 On the day of surgery vials will be collected from the fridge and take them to the 
breast imaging until at a previously specified time. 
 Specimen is collected from the operating theatre, and taken to the breast imaging 
unit for sample collection. 
 14G core biopsy samples - normal stroma, reactive stroma and tumour, identified 
using shear wave ultrasound elastography 
o A shear wave image of each sample site shall also be recorded. 
 Samples will be delivered back to the same fridge. 
o The tissue (in RNA later) is then transferred into an appropriate fridge at 
4°C until such a time (up to 5-7 days) as it can be transferred to a -20°C 
freezer (L6012) (to  be stored for up to 1 month), or processed.   
 Using a well-established manufactured kit, RNA shall be extracted from these 
samples to ensure the best quality RNA is stored for further use at -80  ͦC in a 
freezer or will be immediately converted into cDNA as it is more stable – this will be 
dependent on the next steps/microarray procedure. 
 Quality controls of the material will include – Aligent Tape station (and Invitrogen 
Qubit 2.0 Fluorometer). 
 These samples shall be used as appropriate for differential gene reaction studies 
such as microarray, allowing expression comparison between tumour, reactive and 
normal stroma
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